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A B S T R A C T
Background
Medications with anticholinergic properties are commonly prescribed to older adults. The cumulative anticholinergic eFect of all the
medications a person takes is referred to as the 'anticholinergic burden' because of its potential to cause adverse eFects. It is possible that
high anticholinergic burden may be a risk factor for development of cognitive decline or dementia. There are various scales available to
measure anticholinergic burden but agreement between them is oKen poor.
Objectives
To assess whether anticholinergic burden, as defined at the level of each individual scale, is a prognostic factor for future cognitive decline
or dementia in cognitively unimpaired older adults.
Search methods
We searched the following databases from inception to 24 March 2021: MEDLINE (OvidSP), Embase (OvidSP), PsycINFO (OvidSP), CINAHL
(EBSCOhost), and ISI Web of Science Core Collection (ISI Web of Science).
Selection criteria
We included prospective and retrospective longitudinal cohort and case-control observational studies with a minimum of one year' follow-
up that examined the association between an anticholinergic burden measurement scale and future cognitive decline or dementia in
cognitively unimpaired older adults.
Data collection and analysis
Two review authors independently assessed studies for inclusion, and undertook data extraction, assessment of risk of bias, and GRADE
assessment. We extracted odds ratios (OR) and hazard ratios, with 95% confidence intervals (CI), and linear data on the association between
anticholinergic burden and cognitive decline or dementia. We intended to pool each metric separately; however, only OR-based data were
suitable for pooling via a random-eFects meta-analysis. We initially established adjusted and unadjusted pooled rates for each available
anticholinergic scale; then, as an exploratory analysis, established pooled rates on the prespecified association across scales. We examined
variability based on severity of anticholinergic burden.
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Main results
We identified 25 studies that met our inclusion criteria (968,428 older adults). Twenty studies were conducted in the community care
setting, two in primary care clinics, and three in secondary care settings. Eight studies (320,906 participants) provided suitable data for
meta-analysis. The Anticholinergic Cognitive Burden scale (ACB scale) was the only scale with suFicient data for 'scale-based' meta-
analysis. Unadjusted ORs suggested an increased risk for cognitive decline or dementia in older adults with an anticholinergic burden (OR
1.47, 95% CI 1.09 to 1.96) and adjusted ORs similarly suggested an increased risk for anticholinergic burden, defined according to the ACB
scale (OR 2.63, 95% CI 1.09 to 6.29). Exploratory analysis combining adjusted ORs across available scales supported these results (OR 2.16,
95% CI 1.38 to 3.38), and there was evidence of variability in risk based on severity of anticholinergic burden (ACB scale 1: OR 2.18, 95%
CI 1.11 to 4.29; ACB scale 2: OR 2.71, 95% CI 2.01 to 3.56; ACB scale 3: OR 3.27, 95% CI 1.41 to 7.61); however, overall GRADE evaluation of
certainty of the evidence was low.
Authors' conclusions
There is low-certainty evidence that older adults without cognitive impairment who take medications with anticholinergic eFects may be
at increased risk of cognitive decline or dementia.
P L A I N   L A N G U A G E   S U M M A R Y
The impact of medications with anticholinergic e4ects on future problems with memory and thinking
What was the aim of this review?
Medicines can be classified by their ability to block the action of a chemical signalling system in the body called the cholinergic
system. Medicines that do this are said to have anticholinergic eFects. There are various measurement scales to quantify the eFects of
anticholinergic medicines. The overall anticholinergic eFect caused by all the anticholinergic medications a person is taking is referred to
as 'anticholinergic burden.'
We aimed to investigate if older people who have no problems with memory or thinking are more likely to develop dementia when
prescribed anticholinergic medicines than people who are not prescribed these medicines.
Anticholinergic burden ratings can vary with the scale used because diFerent scales score medicines in diFerent ways. Therefore, we also
wanted to know if any particular anticholinergic burden measurement scale was more strongly associated with increased risk of dementia
than other scales.
Key messages
There may be a link between anticholinergic medicine use and future risk of dementia. However, there are limitations in the published
evidence, and we cannot say definitively if dementia is caused by the anticholinergic medicines themselves or by other factors. There were
too few studies to allow us to compare the various anticholinergic measurement tools.
What was studied in the review?
There are more than 40 million older people worldwide living with dementia. These numbers are expected to rise to over 100 million by
2050 and at present there are very limited treatment options available. Therefore, it is important to identify factors that may increase the
risk of dementia.
Because the cholinergic system in the brain plays an important role in learning and memory, there are theoretical reasons to believe
that medications with anticholinergic eFects could cause future dementia. Research has suggested that these medications may have
unintended eFects on memory and thinking, potentially resulting in dementia. If this is the case, one way to reduce the numbers of older
people who develop dementia may be to avoid prescribing these medicines. Many commonly used medications have anticholinergic
eFects, for example medications for hay fever, insomnia (diFiculty getting to sleep or staying asleep for long enough to feel refreshed),
and depression.
In this review, we investigated the link between anticholinergic medicines, as measured by various measurement scales, and future
dementia.
What were the main results of the review?
We found 25 studies, including 968,428 people aged 50 years or more. Despite the relatively large number of studies, diFerences in design
and methods only allowed us to combine a few of them in analyses. We found that there is a consistent link between use of anticholinergic
medicines and risk of future dementia. We cannot say if these medicines play a causal role; however, if they do, taking these medicines
could potentially double a person's risk of dementia.
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Of the anticholinergic measurement scales available, we could assess one commonly used tool – the 'Anticholinergic Cognitive Burden
scale.' If this scale identified someone as having high anticholinergic burden, the risk of future dementia was more than two times higher
than for someone with no anticholinergic burden.
The evidence included in this review was of a low quality overall and may have exaggerated the strength of the association between
anticholinergic medicines and dementia. For example, anticholinergic medicines may be prescribed for the early symptoms of dementia.
This would give a strong link but would not imply that the medicine caused the memory problems. Similarly, there is a risk that studies
are only published when they show an association between anticholinergic medicines and future dementia. It may be that the only way to
truly establish if anticholinergic medications are associated with future dementia would be to conduct a study where some people have
their anticholinergic medications stopped or changed to an alternative and others continue their usual medications.
How up to date was this review?
We searched for studies published up to 24 March 2021.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Older adults with anticholinergic burden compared with older adults with no
anticholinergic burden for dementia
Older adults with anticholinergic burden compared with older adults with no anticholinergic burden for dementia
Patient or population: older adults without cognitive impairment at baseline
Settings: mixed
Intervention: older adults with an anticholinergic burden (defined according to the Anticholinergic Cognitive Burden scale)



















Findings were restricted to studies included in our
primary analysis evaluating the association be-
tween anticholinergic burden (as defined by the
Anticholinergic Cognitive Burden scale) and risk
of cognitive decline or dementia, independent of
age, sex, and comorbidities. Evidence indicates an-
ticholinergic burden may increase the odds of de-
veloping future cognitive decline or dementia.
CI: confidence interval; OR: odds ratio.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: we are very uncertain about the estimate.
a Campbell 2016; Hafdi 2020; Hsu 2017; Richardson 2018. DiFerences in design and methods restricted suitability of available studies for
pooling in meta-analysis to these four studies.
bTwo of four studies were at high risk of bias, with issues around reverse causation. The remaining two studies were at unclear risk of bias,
one of which had unclear risk of bias due to reverse causation. Therefore, downgraded one level for serious risk of bias.
cThe confidence intervals of our pooled odds ratio diFered by more than five points. Downgraded one level for imprecision.
dWe were unable to evaluate risk of bias via a funnel plot; however, risk of publication bias was assumed within this literature unless
evidence was found to the contrary. Downgraded one level.
eA trend of increasing risk based on severity of anticholinergic burden was apparent in subgroup analysis, with the odds ratios increasing
linearly from 'low severity' to 'high severity.' Upgraded one level.
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B A C K G R O U N D
Description of the condition
Cognition (or cognitive function) is the mental process of acquiring
knowledge and understanding through experience, senses, and
thought. It includes the domains of memory, language, attention,
executive functioning, and visuospatial processing. Cognitive
impairment is the disruption of functioning of any one of these
domains. Cognitive function may be assessed in detail using a
battery of neuropsychological tests covering multiple domains;
although in clinical practice, brief assessment tools such as the
Mini Mental State Examination (MMSE) or Montreal Cognitive
Assessment (MoCA) are oKen used (Folstein 1975; Nasreddine
2005).
Dementia is a syndrome of decline in cognitive function beyond
that expected from normal ageing and to an extent that interferes
with usual functioning. It may aFect memory, thinking, orientation,
comprehension, calculation, learning capacity, language, and
judgement. There are a variety of internationally accepted
diagnostic criteria for dementia, the most widely used of which
are included in the World Health Organization International
Classification of Diseases (ICD) and the American Psychiatric
Association Diagnostic and Statistical Manual of Mental Disorders
(DSM). The most recent iteration of the DSM (DSM-5) refers to 'major
neurocognitive disorder' instead of dementia.
The labels of 'dementia' or 'major neurocognitive disorder'
encompass a variety of pathologies, with specific diagnostic criteria
also available for pathologically defined dementia subtypes, such
as the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) criteria for dementia
due to Alzheimer's disease (McKhann 1984; McKhann 2011);
McKeith criteria for Lewy body dementia (McKeith 2005); Lund
criteria for frontotemporal dementias (McKhann 2001); and the
National Institute of Neurological Disorders and Stroke and the
Association Internationale pour la Recherche et l'Enseignement
en Neurosciences (NINDS-AIREN) criteria for vascular dementia
(Román 1993).
An individual may experience a decline in cognition that is not
enough to merit a label of dementia but that is more than would be
expected as part of ageing. An objective cognitive impairment that
is not severe enough to have a significant impact on daily activities
is referred to as a mild cognitive impairment (MCI). This is a risk
factor for future dementia as one in five may go on to develop
dementia within five years (Petersen 2001).
Dementia and cognitive decline are major public health issues.
There are currently more than 40 million people worldwide with
dementia due to Alzheimer's disease – the most common subtype
– and this number is projected to increase to more than 100
million by 2050 (Prince 2016). Dementia costs were estimated at
USD 818,000 million in 2015, equivalent to 1.1% of global gross
domestic product. It is estimated that by 2030, the global cost
of dementia could grow to USD 2,000,000 million, which could
overwhelm health and social care systems (Wimo 2017). The total
cost of dementia to the UK alone is GBP 34,700 million, of which GBP
4,900 million is paid by the National Health Service (NHS) and GBP
15,700 million is paid by social care. The remainder is paid by those
living with dementia and their families, and is classified as unpaid
social care or private care (Alzheimer's Society 2019).
A number of prognostic factors have been associated with the onset
of dementia, including age, sex, premorbid intelligence, genetics,
medical conditions (e.g. diabetes, hypertension), and lifestyle
factors (e.g. physical inactivity) (Livingston 2017). Identification
of prognostic factors could assist healthcare professionals in
predicting outcomes for people with cognitive syndromes and
help policymakers in planning for future population healthcare
needs. Identification of modifiable prognostic factors are potential
targets for preventing or delaying the onset of cognitive decline and
dementia.
Description of the prognostic factor
A prognostic factor is any measure that is associated with a future
clinical outcome. The prognostic factor of interest for this review is
anticholinergic burden from medication use.
Numerous medications commonly used in older adults have
anticholinergic properties. Some medications, such as oxybutynin
(for overactive bladder), exert their intended action through
their anticholinergic activity. For other medications, such as
amitriptyline for depression, anticholinergic activity is probably
incidental to their intended mechanism of action. It is common for
older adults to be taking multiple medications with anticholinergic
properties (Myint 2015).
Even medications that have low anticholinergic activity
individually may contribute to a significant overall anticholinergic
eFect if a person is taking several of them. This can be quantified
as the anticholinergic burden. There is a reported relationship
between anticholinergic burden and various adverse health
outcomes (Singh 2008). It has been suggested that exposure
to high anticholinergic burden is associated with cognitive
decline and dementia in older adults (Fox 2014). Anticholinergic
burden measures are used in primary and secondary care
as part of the medication review process. Such reviews are
increasingly recommended for older adults. The quantification of
anticholinergic burden is designed to assess risk of future adverse
events. Based on the anticholinergic burden score, clinicians
may recommend reducing or replacing certain medications.
Use of measures of anticholinergic burden to guide treatment
decisions is entering clinical practice. The most recent National
Institute for Health and Care Excellence (NICE) dementia guideline
recommends considering anticholinergic burden as a factor that
may be contributing to cognitive impairment and suggests using
a validated scale to measure anticholinergic burden (NICE 2018).
To date, anticholinergic burden has been considered largely as
a 'stand-alone' prognostic factor (not as part of a multifactorial
prediction model).
Measures of anticholinergic burden
Anticholinergic burden can be measured using a variety of
approaches. There is no consensus on which anticholinergic
burden measures provide the most accurate and clinically
useful prognostic information. Generally, anticholinergic burden
measures use a person's medication list and assign a score to
certain medications. A cumulative total based on all prescribed
medications is then calculated. Although these measures should be
Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive
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similar, overlap is limited; they include diFering medications and
assign diFering scores to these medications.
Our literature scoping suggests that 18 tools to measure
anticholinergic burden have been published. One large population
cohort (UK Biobank) reported that anticholinergic burden was
strongly associated with future adverse health outcomes regardless
of which anticholinergic burden measure was used (Hanlon 2020).
However, at the individual patient level, there was substantial
variability in the anticholinergic burden score generated by each
measure. Methodologies for developing respective scales vary
significantly: where some incorporate expert clinical opinion
in their development and are designed to measure both
central and peripheral anticholinergic eFects, others focus on
serum radioreceptor anticholinergic activity assay or muscarinic
receptor aFinity measurements and may only capture peripheral
anticholinergic eFects. Therefore, any prognostic review should
be completed at the individual scale level in addition to creating
summary estimates for all anticholinergic burden measures.
Prior to adoption in clinical practice, there should be a
comprehensive assessment of the available literature to describe
whether anticholinergic burden is a true prognostic factor,
particularly adjusting for other dementia risk factors that may also
be associated with anticholinergic prescribing. The relationship
may vary based on the duration of the drug exposure period or via
diFerences in clinical and demographic characteristics in specific
clinical or community-based settings. If anticholinergic burden is a
prognostic factor, the strength of the association and the quality of
the supporting evidence should also be described. Looking at the
prognostic properties of each anticholinergic burden measure may
assist in choosing a preferred scale.
Why is it important to do this review?
Increasing clinical interest in anticholinergic burden is
accompanied by a growth in the research literature on
anticholinergic burden as a prognostic factor. However, results
from individual studies of anticholinergic burden and cognition or
dementia are conflicting. Not all published papers have followed
best practice in design, conduct, or reporting; and comparative
strength of associations between respective scales and dementia
has not been established. Thus, there is uncertainty around
the clinical utility of anticholinergic burden and, consequently,
inconsistency in clinical practice and guideline recommendations.
In this systematic review, we aimed to estimate the prognostic
utility (adjusted and unadjusted) of diFerent anticholinergic
burden measures for predicting cognitive decline or dementia in
a cognitively healthy older adult population, and to assess the
quality of the supporting evidence.
O B J E C T I V E S
Primary objective
• To assess whether anticholinergic burden, as defined at the level
of each individual scale, is a prognostic factor for future cognitive
decline or dementia in cognitively unimpaired older adults.
Secondary objectives
• To assess whether the strength of association between
anticholinergic burden and future cognitive decline or dementia
diFers in various settings (e.g. primary care, secondary care, or
community settings).
• To compare the prognostic validity of diFerent anticholinergic
burden scales.
• To examine the eFect of duration of exposure and duration
of follow-up on the anticholinergic burden dementia risk
association.
M E T H O D S
We followed best practice in design, conduct, and reporting of
our prognosis review as detailed in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2019). The review was
supported by the Cochrane Prognostic Methods Group, partners
within the Cochrane Mental Health and Neuroscience Network, and
the UK National Institute for Health Research Complex Reviews
Support Unit (NIHR CRSU).
We used the PICOT (Patient/Problem; Intervention; Comparison;
Outcome; Timing) system to design our review question (Schardt
2007) (Table 1). As recommended by the Cochrane Prognosis
Methods Group, we followed guidelines suggested by Riley 2019, to
ensure that our review was designed, conducted, and reported in
keeping with best practice recommendations.
Criteria for considering studies for this review
Types of studies
We included prospective and retrospective longitudinal cohort
and case-control observational studies. We did not include cross-
sectional studies, as it is not possible to determine prognosis from
this design. We did not include prospective case studies, defined
here as having fewer than 20 participants. We excluded studies that
were published only as abstracts or posters at conferences, as these
have not undergone peer review.
Types of participants
We included any studies that recruited older adults (as defined
by the authors, but with minimum median/mean age 50 years
at baseline) who were free of any known cognitive diagnosis
(MCI, dementia, delirium) at time of recruitment and at time of
application of the anticholinergic burden measure. We did not
exclude studies that did not assess cognition at baseline; however,
where a mixed population was recruited, we only included the
study if the prevalence of dementia was less than 7% in a
community sample (similar to general population prevalence in
unselected older adults). We also included studies that recruited
mixed populations in a hospital setting, where the prevalence
of dementia was higher, provided that it was conducted in an
unselected (i.e. consecutive admissions) sample.
We included studies where initial recruitment was in primary care,
secondary care, and community settings. Participants in these
respective settings may diFer in important demographics (e.g.
mean age, clinical or lifestyle factors) that could alter the strength
of the association between anticholinergic burden and cognitive
decline or dementia. We defined primary care as settings in which
the patient self-presented to a non-specialist service, such as
general practice. We defined secondary care as any settings where
patients were referred for expert care, including general hospitals
and more specialist settings. We defined community settings as
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settings in which the cohort was completely unselected, that is
'population screening.'
As this review focused on prognosis in people who were cognitively
well, we did not include studies conducted in care-home settings
where the prevalence of cognitive syndromes is substantial.
We made no other restriction based on comorbidity or
polypharmacy but recorded these factors in our data extraction.
We assessed whether comorbid conditions that are associated with
dementia (depression, stroke, other neurological diseases) were
measured and considered any potential impact of this in our 'Risk of
bias' assessment. We included studies conducted in specific patient
subgroups, such as Parkinson's disease or stroke, provided they
met our other inclusion criteria.
Index prognostic factor
The prognostic factor of interest was anticholinergic burden from
medications. We included any study that used an ordinal scale
that purported to measure cumulative exposure to medications
with anticholinergic properties. Scales did not need to be described
as validated for prediction of cognitive outcomes. Previously
identified scales are listed in Appendix 1.
DiFerent approaches to quantifying anticholinergic burden have
been used. Some scales sum ordinal scores for each relevant drug
to give a continuous measure; others create a summary ordinal
hierarchical measure that scores, for example, 0 to 3 or 0 to 4
based on the cumulative anticholinergic exposure. Most scales
define thresholds of 'low' and 'high' burden. As our focus in this
review was on the extent of anticholinergic burden, we did not
include studies that established anticholinergic exposure via a
simple dichotomised present/absent method.
Some anticholinergic burden measures were developed
specifically to predict dementia, while others were developed
to predict other adverse events, including death. Anticholinergic
activity should be an objective drug eFect, and so we included
any anticholinergic burden measure, not just those developed for
cognitive outcomes.
We did not choose a particular measure of primary interest as there
is no consensus on the preferred measure, and there is substantial
heterogeneity in clinical practice. However, if the Drug Burden Index
(DBI) scale was utilised, we only included data if anticholinergic
burden data were reported separately.
Comparator prognostic factors
We were interested in the value of anticholinergic burden as
a prognostic factor over and above other prognostic factors
that may be common in this population. Hence, while we
included studies that only assessed the unadjusted anticholinergic
burden prognosis, we also evaluated the prognostic eFect of
anticholinergic burden adjustment for core variables identified as
fundamental to the putative link between anticholinergic burden
and dementia. These variables were selected on the basis of
a Delphi discussion between the review authors and a wider
multicentre collaborative, working in the field of anticholinergic
burden research (Appendix 2). The chosen core variables were
age, sex, and comorbidity. We recognise that comorbidity may
be described in various ways. We accepted any classification that
the original study authors defined as a measure of comorbidity,
including measures that oFered quantitative data, for example,
number of medications, number of medical conditions listed, or
formal measures such as the Charlson Comorbidity Index.
We assessed use of additional adjustments in our 'Risk of bias'
assessment.
Outcome measures
Primary outcome: we included any study that assessed incident
dementia, MCI, or cognitive decline (i.e. change on a measure
of cognitive function) as an outcome. We accepted any validated
diagnostic criteria for dementia or MCI. For the outcome
of cognitive decline, we accepted any multidomain cognitive
assessment tool that is validated for the direct assessment of
cognition. We did not include papers that only measured a single
cognitive domain.
Timing: we accepted assessment for cognitive decline or dementia
at one year or longer following baseline anticholinergic burden
assessment to mitigate the risk of reverse causality between any
observed risk associations.
Search methods for identification of studies
Electronic searches
As reporting of prognostic factor studies is variable, it can be
challenging to identify all relevant studies. We adopted the
procedure proposed by Geersing 2012 to maximise our ability to
identify relevant prognostic studies. Specifically, as we searched for
one prognostic factor, we did not adopt any specific search filter,
but instead adopted a search that combines our prognostic factor
(anticholinergic burden) with the disease outcome (dementia/
cognitive impairment).
We searched the following databases: MEDLINE (1946 to 24 March
2021; OvidSP), Embase (1974 to 24 March 2021; OvidSP), PsycINFO
(1806 to 24 March 2021; OvidSP), CINAHL (Cumulative Index to
Nursing and Allied Health Literature) (1950 to 24 March 2021;
EBSCOhost), and ISI Web of Science Core Collection (1928 to 24
March 2021; ISI Web of Science) (Appendix 3). We applied no
language restrictions.
Searching other resources
We supplemented this with handsearches of all included studies
and identified systematic reviews.
Data collection and analysis
Selection of studies
We used Covidence systematic review soKware to identify relevant
studies (Covidence). The review group Information Scientist
performed a 'first pass' screen to remove clearly irrelevant titles.
Two review authors (MT and SE) independently screened studies
identified via our search method. Titles and abstracts were
screened in the first instance, with the full text of potentially
relevant studies then accessed to determine if the study met
our inclusion criteria. In case of disagreement, a third review
author (TQ) acted as arbiter and made the final decision on study
inclusion/exclusion.
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Data extraction and management
Two review authors (MT and SE) extracted the data to a piloted
proforma based on the CHARMS-PF (CHecklist for critical Appraisal
and data extraction for systematic Reviews of prediction Modelling
Studies, adapted for prognostic factors) template (Riley 2019). We
contacted authors for missing data where required. We selected
two studies to trial our data extraction proforma (Gray 2015;
Richardson 2018a). We extracted all data onto a standard form
(Appendix 4).
Assessment of methodological quality
Two review authors (MT and SE) independently used the
QUIPS (Quality in Prognosis Studies) checklist (Hayden 2012),
assessing the included studies across the domains of: study
participation; study attrition; prognostic factor measurement;
outcome measurement; adjustment for covariates; reverse
causation; statistical analyses; and reporting. We used the QUIPS
anchoring statements but modified the content to suit our review
topic based on consensus within the review author team. We
judged each domain as low risk of bias, moderate risk of bias, or
high risk of bias (Appendix 5). In cases of uncertainty we contacted
original study authors for clarification, where possible.
Discussing reporting deficiencies: prognosis research is
frequently confounded by poor reporting and possible publication
bias. We supplemented our 'Risk of bias' assessment with a
narrative discussion of reporting issues, highlighting when missing
information may have aFected results. Prognostic factor studies
oKen do not register protocols, increasing the risk that not all
studies (published and unpublished) will be identified, and there
is a risk of small-study eFects (in which smaller studies with
higher odds ratios (ORs) are more likely to be published than
smaller studies with non-significant ORs), which can bias meta-
analyses (Peat 2014; Riley 2019). We used sensitive search filters for
the disease (dementia) and the prognostic factor (anticholinergic
burden) without any specific filter for prognostic research to
increase retrieval, and attempted to examine the likelihood of
small-study eFects in our review by generating a funnel plot.
Data synthesis
We evaluated risk of future cognitive decline or dementia for
anticholinergic drug users against non-users. Where possible, we
pooled summary estimates for each anticholinergic burden tool
individually; then, as an exploratory analysis, pooled summary
estimates across all scales. We conducted each meta-analysis
in two ways. First, as an all-encompassing 'any anticholinergic
drug use' variable; second, as an ordinal, hierarchical variable
in which low, moderate, and high users were pooled separately,
to investigate possible diFerential relationships based on
anticholinergic burden severity. Low users were defined as those
with a cumulative score of 1 on an anticholinergic scale; moderate
users were defined as those with a cumulative score of 2 on an
anticholinergic scale; high users were defined as those with a
cumulative anticholinergic scale score of 3 or above.
We pooled data in two separate ways. In the first instance, we
pooled data obtained from unadjusted analyses. In the second
instance, we pooled data from fully adjusted analyses, provided
age, sex, and comorbidity were controlled for as a minimum.
We pooled ORs and hazard ratios separately. We planned to
calculate standardised mean diFerence (SMD) for linear data and
pool this separately from dichotomous outcome data. Where data
were not available, we attempted to estimate data based on
methods suggested by Tierney 2007. Where data were suFiciently
similar to permit pooling, we used a random-eFects approach
given our expectation of high heterogeneity between studies. We
used Comprehensive Meta- Analysis soKware to conduct all meta-
analyses (Comprehensive Meta-Analysis Version 3).
We conducted a sensitivity analysis, restricting to studies that had
no high risk of bias domains.
For secondary (subgroup) analysis, we assessed risk by setting.
We also conducted analysis based on duration of follow-up. We
created categories of one to five years, and longer than five
years and considered pooled rates for each timeframe individually.
These additional outcomes were decided upon through discussion
among the review authors.
We planned to assess exposure, including exposure before
enrolment into the study and exposure during the study.
Finally, we planned to conduct a comparative analysis of the
prognostic performance of the diFering anticholinergic burden
measures using a network meta-analysis.
Investigation/description of heterogeneity
We described heterogeneity narratively based on consistency of
association and eFect size between anticholinergic burden and
future cognitive decline or dementia, measurement of prognostic
factor, outcome measurement and definition, and study design. We
did not employ the I2 statistic in our evaluation of heterogeneity. In
prognosis research, individual studies oKen have large sample sizes
resulting in narrow confidence intervals (CIs); this can cause high
I2 values even if inconsistency between studies is moderate (Iorio
2015).
It is possible that observed associations between anticholinergic
drugs and future cognitive decline or dementia are driven by
uncontrolled variables. Number of medical conditions or overall
polypharmacy are two possible moderators of observed eFects and
could diFer by setting. To investigate this, we planned to conduct
a meta-regression based on study recruitment setting (primary
versus secondary care versus community care), comorbidity
('number of comorbidities' controlled for as a covariate, yes/no),
and polypharmacy (controlled for as a covariate, yes/no).
Grading the evidence
We used the GRADE approach to evaluate our overall confidence
in the results. We adapted the GRADE approach to suit prognosis
research using methods consistent with Huguet 2013. Specifically,
we evaluated reported evidence in the following eight areas.
• Phase of investigation: phase 3 explanatory studies derived
from bespoke cohort study designs that seek to explain
the mechanisms behind an underlying association between
anticholinergic burden and dementia/cognition were be
considered a high level of evidence. Phase 2 explanatory studies
that seek to confirm an independent association between
anticholinergic burden and dementia/cognition were treated
as moderate evidence, and hypothesis-generating phase 1
explanatory studies were treated as weak evidence for any
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association between anticholinergic burden and dementia/
cognition.
• Study limitations: we used the previously described QUIPS tool
to evaluate the overall risk of bias of included studies. Our
GRADE judgement was based upon the overall certainty of the
evidence, that is, if most (more than 50%) included studies were
considered at high risk of bias in their reported association
between anticholinergic burden and dementia/cognition, we
downgraded the evidence accordingly.
• Inconsistency: we downgraded the evidence if associations
between ACB and dementia/cognition were heterogeneous
(i.e. the reported ORs/hazard ratios fell either side of 1.0
on a forest plot, the measure of the prognostic factor was
highly variable, outcome measurement was highly variable, and
methodological heterogeneity due to study design/potential
biases study design); and if the P value was low for the test of the
null hypothesis that all studies in a meta-analysis have the same
underlying magnitude eFect.
• Indirectness: we downgraded the studies where their
investigation did not fully match with our broader review
question. We considered two areas of indirectness when judging
if evidence should be downgraded on this basis: 1. if the
population in the included studies only represented a subset
of the population of interest (e.g. if only very old, i.e. older
than 80 years, were assessed); 2. if the outcome investigated in
the included studies was overly restricted (e.g. if the included
studies explored only the association between anticholinergic
burden and Alzheimer's dementia), then the evidence for
the association between anticholinergic burden and all-cause
dementia was downgraded for indirectness.
• Imprecision: we downgraded the evidence if there were
insuFicient numbers in the meta-analysis or if the CIs were wide.
We did not set an absolute value, but assessed this in the context
of eFect size and minimally important clinical diFerence.
• Publication bias: due to inherent issues regarding publication
bias in prognostic research, we adopted the default position
that publication bias was likely and downgraded the evidence
unless our assessment of publication bias provided significant
evidence to the contrary (i.e. a symmetrically distributed
funnel plot, and evidence that the prognostic factor has been
investigated in numerous cohort studies).
• EFect size: we upgraded our confidence in the eFect estimate
when the eFect size was moderate to large (e.g. a hazard ratio of
2.5 or above).
• Exposure-response gradient: we upgraded our confidence in the
eFect estimate if there was evidence (via subgroup analysis) that
a longer duration of anticholinergic burden was associated with
an increased risk of dementia/cognitive decline. Similarly, we
upgraded the evidence if there was an incremental increase in
eFect size with increasing anticholinergic burden.
R E S U L T S
Description of studies
Results of the search
Our search identified 16,391 results. We identified a further four
eligible studies via handsearching references. AKer deduplication
and assessment of abstracts, we assessed 93 studies via full-
text screening, of which 25 met our inclusion criteria. See
Characteristics of excluded studies table for reasons for exclusion.
Figure 1 shows the PRISMA flow chart (Moher 2009).
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Included studies
Twenty-two studies were longitudinal 'cohort' designs and three
were 'case control' studies (Coupland 2019; Richardson 2018;
Yarnall 2015). All but one study (Iyer 2020) were conducted in
a retrospective fashion, utilising databases in which participant
information was obtained for a purpose other than investigating
the association between anticholinergic burden and risk of future
cognitive decline or dementia. Study sample sizes ranged from
102 to 324,703 participants and were conducted in Europe, North
America, Asia, and Oceania: specifically, eight in the US; six in the
UK; two in Taiwan; and one each in Sweden, Canada, France, Italy,
Australia, Germany, Netherlands, Ireland, and South Korea. Follow-
up times for development of cognitive decline or dementia ranged
from one to 11 years. See Characteristics of included studies table
for details.
Participant characteristics
The review included 968,428 older adults; about 60% were
women, mean/median age range across studies was 52 to
83 years. Participants were recruited overwhelmingly from
community settings (963,081; 99.4%); 3716 (0.4%) were recruited
via attendance at primary care clinics and 1525 (0.1%) were
recruited in a secondary care setting. Most included studies were
inclusive of the general 'older adult' population. However, two
studies were conducted in people with Parkinson's disease (Sheu
2019; Yarnall 2015); one study was conducted in people with an
overactive bladder (Iyer 2020); and one study was restricted to a
'young old' population (Low 2009).
Prognostic factor
Anticholinergic burden was assessed via 10 distinct methods.
Eight studies used more than one method (Ancelin 2006; Brombo
2018; Coupland 2019; Gray 2015; Hsu 2017; Joung 2019; Kashyap
2014; Richardson 2018). Nineteen studies used an anticholinergic
measurement scale: 17 used the Anticholinergic Cognitive Burden
scale (ACB scale) (Brombo 2018; Campbell 2016; Chuang 2017;
Coupland 2019; Fox 2011a; Grossi 2019; Hafdi 2020; Hsu 2017; Iyer
2020; Joung 2019; Kashyap 2014; Koyama 2014; Moriarty 2020;
Richardson 2018; Risacher 2016; Shah 2013; Sheu 2019), four used
the Anticholinergic Drug Scale (ADS) (Kashyap 2014; Low 2009;
Richardson 2018; Yarnall 2015), three used the Anticholinergic Risk
Scale (ARS) (Brombo 2018; Hsu 2017; Kashyap 2014), and two used
the anticholinergic component of the Drug Burden Index (DBI-ach)
(Hsu 2017; Kashyap 2014). One study evaluated anticholinergic
burden via a list defined by Chew 2008 (Jessen 2010); one study
used a clinician-rated anticholinergic score (Han 2008); one study
used the Anatomical Therapeutic Chemical classification system
(Papenberg 2017); two studies used the ACB scale in combination
with Beers criteria (Coupland 2019; Joung 2019); one study used
a literature review of drugs' anticholinergic activity (Whalley
2012); one study used Beers criteria combined with a literature
review (Gray 2015); and one study used serum radioreceptor assay
combined with a summation of mean estimated clinical eFects of
specific drugs, established via a pharmacologist, physician, and
biologist (Ancelin 2006).
Outcome measures
Eleven studies reported assessing for dementia as an outcome
(Ancelin 2006; Coupland 2019; Gray 2015; Grossi 2019; Hafdi
2020; Hsu 2017; Jessen 2010; Joung 2019; Richardson 2018; Sheu
2019; Whalley 2012); three reported MCI and dementia combined
(Campbell 2016; Chuang 2017; Risacher 2016); four reported MCI
alone (Ancelin 2006; Kashyap 2014; Low 2009; Yarnall 2015);
and 13 reported multidomain cognitive impairment based on
standardised cognitive test scores (Ancelin 2006; Brombo 2018;
Fox 2011a; Han 2008; Iyer 2020; Kashyap 2014; Koyama 2014;
Low 2009; Moriarty 2020; Papenberg 2017; Risacher 2016; Shah
2013; Whalley 2012; Yarnall 2015). Six studies established dementia
or MCI via a consensus diagnosis based on a multidisciplinary
evaluation (Campbell 2016; Chuang 2017; Gray 2015; Hafdi 2020;
Jessen 2010; Whalley 2012). Three studies established dementia
or MCI via a clinical examination from a single expert (e.g.
neurologist, psychiatrist) (Ancelin 2006; Kashyap 2014; Low 2009).
Five studies relied upon clinical codes recorded in medical records
for diagnoses (Coupland 2019; Hsu 2017; Joung 2019; Richardson
2018; Sheu 2019), and one study employed a computer algorithm
(Grossi 2019). Method for diagnosing dementia or MCI was unclear
in two studies (Risacher 2016; Yarnall 2015). Dementia was
diagnosed according to the DSM (APA 2000) criteria in seven studies
(Ancelin 2006; Campbell 2016; Chuang 2017; Gray 2015; Grossi 2019;
Hafdi 2020; Jessen 2010), and ICD-10 (WHO 1992) criteria in three
studies (Jessen 2010; Sheu 2019; Whalley 2012). Three studies did
not explicitly state dementia diagnostic criteria (Coupland 2019;
Hsu 2017; Richardson 2018). MCI was diagnosed according to DSM-5
criteria in one study (Kashyap 2014), Peterson criteria (Petersen
2001) in one study (Chuang 2017), Jack criteria (Jack 1999) in one
study (Low 2009), DSM III criteria in one study (Campbell 2016),
Stockholm consensus group criteria (Winbald 2004) in one study
(Ancelin 2006), and Movement Disorder Society criteria (Litvan
2012) in one study (Yarnall 2015). One study did not state criteria by
which MCI was defined (Risacher 2016).
Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive
syndrome (Review)









Cochrane Database of Systematic Reviews
Risk of bias in included studies
Nineteen studies were at high risk of bias in at least one domain. No
studies were at low risk of bias in every domain.
Most common issues were around lack of control for reverse
causation (14 studies at high risk of bias), study attrition/
missing data (nine studies at high risk of bias), and population
generalisability (nine studies at high risk of bias).
Only two studies employed a dual approach to establishing
medication use that would enhance identification of both
prescription and non-prescription drugs, along with recording
dosage, duration of exposure, and adherence (Fox 2011a; Kashyap
2014). Two studies did not record anticholinergic drug usage at
multiple time points, despite a follow-up duration of more than one
year (Koyama 2014; Risacher 2016).
Most studies controlled for age, sex, and comorbidities as
covariates; however, only 13 studies controlled for psychiatric
conditions, such as depression, that may heighten risk, or even be
prodromal signs of dementia as well as increase anticholinergic
burden (Ancelin 2006; Coupland 2019; Gray 2015; Grossi 2019; Hafdi
2020; Han 2008; Iyer 2020; Joung 2019; Moriarty 2020; Papenberg
2017; Richardson 2018; Sheu 2019; Yarnall 2015).
There were also general issues around good methodological
practice: no protocols were registered; only three studies reported
tests of statistical assumptions in analysis (Joung 2019; Moriarty
2020; Risacher 2016), and no studies reported blinding to outcome
when assessing anticholinergic burden scores (Figure 2).
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Ancelin 2006 ? ? ? ? ? - ?
Brombo 2018 - - ? ? ? - ?
Campbell 2016 - - ? ? ? - ?
Chuang 2017 ? - ? ? ? - ?
Coupland 2019 + ? ? ? + + ?
Fox 2011a ? - + ? ? ? ?
Gray 2015 + ? ? ? + ? ?
Grossi 2019 + - ? ? + + ?
Hafdi 2020 + ? ? ? + ? ?
Han 2008 - ? ? ? + - ?
Hsu 2017 + ? ? ? ? - ?
Iyer 2020 - - ? - + - ?
Jessen 2010 ? ? ? ? - - ?
Joung 2019 + ? ? ? + + ?
Kashyap 2014 ? ? + ? - - -
Koyama 2014 - - - ? ? ? ?
Low 2009 ? ? ? - ? - -
Moriarty 2020 ? + ? ? + ? ?
Papenberg 2017 + - ? ? + - ?
Richardson 2018 + ? ? ? + + ?
Risacher 2016 - ? - ? ? - -
Shah 2013 - ? ? ? ? - ?
Sheu 2019 - ? ? ? + ? ?
Whalley 2012 ? - ? ? ? ? -
Yarnall 2015 - ? ? ? + - -
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Association between anticholinergic burden and
dementia/cognitive decline
Twenty-three of 25 studies reported a significant association
between anticholinergic use and increased risk of cognitive
impairment (of any type). However, specific associations between
anticholinergic use and risk of dementia, MCI, and cognitive decline
were more heterogeneous.
• Dementia: 9/11 studies reported a significantly increased risk
for dementia (Coupland 2019; Gray 2015; Grossi 2019; Hafdi
2020; Hsu 2017; Jessen 2010; Joung 2019; Richardson 2018;
Sheu 2019); two studies reported no association (Ancelin 2006;
Whalley 2012).
• MCI and dementia: 3/3 studies reported significant increased risk
for MCI and dementia combined (Campbell 2016; Chuang 2017;
Risacher 2016).
• MCI alone: 1/4 studies reported significantly increased risk for
MCI (Ancelin 2006); 3/4 studies reported no association (Kashyap
2014; Low 2009; Yarnall 2015).
• Cognitive decline: 12/14 studies reported significantly increased
risk for reduced performance on cognitive tests (Ancelin 2006;
Brombo 2018; Fox 2011a; Han 2008; Kashyap 2014; Koyama
2014; Low 2009; Moriarty 2020; Papenberg 2017; Risacher 2016;
Shah 2013; Whalley 2012); two studies reported no association
(Iyer 2020; Yarnall 2015). Investigated domains were extremely
diverse and aFected domains inconsistently reported. There
were statistically significant declines for memory (seven studies;
Ancelin 2006; Han 2008; Kashyap 2014; Koyama 2014; Moriarty
2020; Papenberg 2017; Risacher 2016), executive functioning
(four studies; Han 2008; Kashyap 2014; Risacher 2016; Whalley
2012), visuospatial construction (one study; Ancelin 2006),
language (two studies; Ancelin 2006; Koyama 2014), processing
speed (two studies; Ancelin 2006; Low 2009), and attention (one
study; Ancelin 2006). Three studies reported a global cognitive
decline on cognitive testing (Brombo 2018; Fox 2011a; Shah
2013).
One study investigated the association between anticholinergic
use and cognitive decline via a univariate regression only
(Kashyap 2014). Choice of comorbidities varied across all studies
that assessed the association via multiple regression (see
Characteristics of included studies table).
A variety of factors influenced the observed association between
anticholinergic burden and cognitive impairment.
Associations diFered by anticholinergic burden score and dosage.
Most studies suggested that a higher anticholinergic burden score/
dosage is more strongly associated with cognitive impairment
than lower scores/dosages. Two studies found the association
was only apparent in those with a low anticholinergic burden
(anticholinergic burden = 1), though both studies had low numbers
of moderate/high anticholinergic burden (Ancelin 2006; Chuang
2017), and one study reported that those with an anticholinergic
burden of 2 or 3 had a shorter duration of exposure and frequency of
use than those with an anticholinergic burden of 1 (Chuang 2017).
Duration of use was a modifying factor in five studies. Three
studies found an association between anticholinergic burden and
cognitive impairment for recurrent/persistent drug users only
(Grossi 2019; Hafdi 2020; Papenberg 2017), while one study found
that continuous use of anticholinergic drugs was more strongly
associated with cognitive impairment than intermittent use (Joung
2019). By contrast, one study found that the gradient of global
cognitive decline was greater for incident users, but not for
prevalent users (Shah 2013); while one study reported a larger
decline in cognitive scores for new users compared to persistent
users, and no significant diFerence in decline on cognitive scores
between discontinued users and non-users (Moriarty 2020).
Drug type was a factor explored in five studies. Three studies
found drug type altered the relationship between anticholinergic
burden and risk of cognitive impairment (Coupland 2019; Hafdi
2020; Richardson 2018). Specifically, antidepressants, analgesics,
anti-Parkinson's, antipsychotics, antiemetics, urological, and
respiratory drugs were significantly associated with increased
risk of cognitive impairment; while antihistamines, cardiovascular,
and gastrointestinal drugs were not. Two studies found risk for
dementia in the highest exposure category was independent of
anticholinergic drug type (Gray 2015; Joung 2019).
The population investigated also appears to be an important
moderator of the association. The two studies that reported
no association between anticholinergic use and future cognitive
impairment (of any type) were conducted in a people with
Parkinson's disease (Yarnall 2015) and overactive bladder (Iyer
2020). All studies that investigated the association in a more
'general' older adult population reported a significant association
of some type.
Meta-analysis
Twelve studies provided OR or hazard ratio (or both) data for
meta-analysis. Thirteen studies provided linear data (Ancelin 2006;
Brombo 2018; Fox 2011a; Han 2008; Iyer 2020; Koyama 2014; Low
2009; Moriarty 2020; Papenberg 2017; Risacher 2016; Shah 2013;
Whalley 2012; Yarnall 2015). However, hazard ratio and linear data
were too heterogeneous to pool; therefore, we report only on the
results of pooled ORs. See Characteristics of included studies table
for the specific covariates controlled for in each study included in
our meta-analyses.
Some of the included papers described associations for various
cognitive outcomes. For our primary cognitive analysis, we had
to prioritise a single outcome. We prespecified that we would
favour data that described the association with incident clinical
dementia. We chose this outcome as we anticipated it would be
most commonly reported and arguably it is the most clinically
relevant. Similarly, some papers included multiple scales that
purport to measure anticholinergic burden. In these instances, we
favoured the ACB scale as we anticipated that this would be the
most commonly used.
Univariate association
Four studies (287,546 participants) provided unadjusted ORs
(Coupland 2019; Hafdi 2020; Kashyap 2014; Richardson
2018). Three of four studies reported ORs for risk of
dementia only; one study reported ORs for cognitive decline
(Kashyap 2014). There were insuFicient numbers to pool ORs
subgrouped by anticholinergic measurement scale; hence, we
pooled rates across all scales. Where studies provided ORs
subgrouped by anticholinergic burden score only, we selected
anticholinergic burden values of 3 or closest to evaluate
'definite' anticholinergic drugs while maximising statistical power
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and minimising heterogeneity. Richardson 2018 subgrouped
cumulative anticholinergic burden score by defined daily dosage
(DDD); therefore, we selected the largest group (DDD greater than 0
to 13) in the ACB scale 3 category. One study reported dosage-based
subgroups only; for this study, the ORs from the largest 'dosage
subgroup' (1 to 90) had asymmetrical CIs, hence we selected the
ORs from the dosage with the second highest participant numbers
('greater than 1900') (Coupland 2019). Pooled rates suggested a
significant increase in risk of cognitive impairment or dementia for
anticholinergic drug users compared to non-users (OR 1.47, 95% CI
1.09 to 1.96) (Figure 3).
 
Figure 3.   Unadjusted analysis: anticholinergic burden and odds of future cognitive decline or dementia.
 
Fully adjusted multivariate model
For our primary analysis on the association between
anticholinergic drug use and risk of cognitive decline or dementia,
three studies (121,833 participants) provided ORs based on use
of the ACB scale exclusively to establish anticholinergic burden
(Campbell 2016; Hsu 2017; Richardson 2018). One additional study
provided ORs aKer contacting the author (Hafdi 2020). One other
study reported ORs in a form that could be included in our ACB
scale meta-analysis (Sheu 2019). However, this study compared
those with a moderate and severe anticholinergic burden against
those with a low burden (instead of against non-users) and
was conducted in people with Parkinson's disease; therefore, we
excluded it from analysis. As in our univariate analysis, we selected
ORs with an ACB score of 3 or closest where multiple ORs were
reported. Total number of ORs pooled for this analysis was six, as
one study provided three suitable ORs due to subgrouping based on
age (Hsu 2017). Results suggest drugs classified as having 'definite'
anticholinergic properties by the ACB scale may have an increased
risk of future cognitive decline or dementia (OR 2.63, 95% CI 1.09 to
6.29) (Figure 4). There were insuFicient studies to establish specific
associations for other anticholinergic measurement scales.
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Figure 4.   Primary analysis: adjusted association between ACB scale and odds of future cognitive decline or
dementia.
 
We ran further analyses to quantify ORs for each 'low', 'moderate',
and 'high' ACB scale subgroup. From Richardson 2018, we selected
the DDD greater than 1460 from each 'low', 'moderate', and 'high'
ACB scale group based on utilising the highest available participant
numbers while maintaining consistency of DDD across subgroups. A
relationship between severity of cumulative anticholinergic burden
and risk of dementia was apparent. Four ORs from two studies
(145,663 participants with low ACB) were pooled for 'low' ACB
(OR 2.18, 95% CI 1.11 to 4.29) (Hsu 2017; Richardson 2018). Four
ORs from two studies (1719 participants with moderate ACB) were
pooled for 'moderate' ACB (OR 2.71, 95% CI 2.01 to 3.56) (Hsu 2017;
Richardson 2018). Five ORs from three studies (8451 participants
with high ACB) were pooled for 'high' ACB (OR 3.27, 95% CI 1.41 to
7.61) (Hafdi 2020; Hsu 2017; Richardson 2018) (Figure 5).
 
Figure 5.   Primary analysis: relationship between severity of anticholinergic burden (defined according to ACB
scale) and odds of future cognitive decline or dementia.
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As an exploratory analysis, we pooled ORs across scales. Seven
studies (317,216 participants) reported ORs suitable for analysis
(Ancelin 2006; Campbell 2016; Coupland 2019; Hafdi 2020; Hsu
2017; Richardson 2018; Whalley 2012). Five of the seven studies
reported the odds for risk of dementia only; one assessed the
odds of developing MCI or dementia (combined) (Campbell 2016),
and one assessed odds of developing MCI only (Ancelin 2006). We
pooled ORs with an anticholinergic burden score of 3 or closest;
or in the case of one study (Coupland 2019), a dosage of 'strong'
anticholinergic drugs of 1 to 90. Pooled rates suggest people taking
anticholinergic drugs may have a significantly increased risk of
future cognitive decline or dementia (OR 2.16, 95% CI 1.38 to 3.38)
(Figure 6).
 
Figure 6.   Exploratory 'cross scale' analysis: adjusted association between anticholinergic burden and odds of
future cognitive decline or dementia.
 
We ran a post-hoc analysis to investigate the association with
dementia specifically (296,523 participants). We removed two
studies that did not assess 'dementia only' as an outcome (Ancelin
2006; Campbell 2016). Results show risk of dementia may be higher
for anticholinergic drug users compared to non-users (OR 2.18,
(95% CI 1.33 to 3.57) (Figure 7).
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Figure 7.   Post hoc analysis: adjusted association between anticholinergic burden and odds of future dementia
specifically.
 
We conducted a sensitivity analysis to investigate the eFect of risk
of bias on our pooled rates. We restricted analysis to three studies
(468,830 participants) that reported ORs but had no high risk of
bias categories (Coupland 2019; Hafdi 2020; Richardson 2018).
Results were consistent with our exploratory analysis: people
taking anticholinergic drugs may be at increased risk of developing
future dementia; however, the size of the risk was lower (OR 1.07,
95% CI 1.04 to 1.09) (Figure 8).
 
Figure 8.   Risk of bias analysis: adjusted association between anticholinergic burden and odds of future cognitive
decline or dementia restricted to low risk of bias studies only.
 
We were unable to formally investigate the possibility of
publication/small-study bias by generating a funnel plot due
to limited study numbers. However, risk of publication bias is
assumed within this field.
Certainty of evidence (GRADE)
The overall quality of evidence from our primary analysis was low.
Evidence was downgraded based on extent of risk of bias within
studies, imprecision, and possible publication bias. Evidence was
upgraded based on the apparent incremental increase in risk
based on severity (low, moderate, and high) of ACB scores. Specific
judgements in each respective domain are shown in Table 2.
Secondary analyses
We conducted a subgroup analysis based on 'setting.' Five studies
(295,666 participants) were conducted in a community setting and
suggested anticholinergic drug users in the community may have
an increased risk of cognitive decline or dementia (OR 2.18, 95%
CI 1.30 to 3.65) (Figure 9) (Coupland 2019; Hafdi 2020; Hsu 2017;
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Richardson 2018; Whalley 2012). There were insuFicient studies
conducted in primary or secondary care to establish pooled rates.
 
Figure 9.   Subgroup analysis: adjusted association between anticholinergic burden and odds of future cognitive
decline or dementia subgrouped by setting.
 
We examined the pooled ORs based on duration of follow-up. Five
studies (295,666 participants) provided suitable ORs for duration
greater than five years (OR 2.18, 95% CI 1.30 to 3.65) (Figure 10)
(Coupland 2019; Hafdi 2020; Hsu 2017; Richardson 2018; Whalley
2012). There were insuFicient studies to investigate OR for one to
five years' follow-up.
 
Figure 10.   Subgroup analysis: adjusted association between anticholinergic burden and odds of future cognitive
decline or dementia subgrouped by duration of follow-up.
 
Duration of exposure to anticholinergic medications was too poorly
reported to be investigated as a source of potential variability
regarding the association between anticholinergic burden and
cognitive decline or dementia.
We were unable to run a meta-regression to investigate the
influence of number of comorbidities controlled for on the
relationship between anticholinergic burden and cognitive decline
or dementia due to lack of study numbers. This was similarly the
case for polypharmacy and setting.
Association based on scale
Low study numbers meant presenting pooled rates for all but
the ACB scale was not possible; hence, we could not conduct a
comparative statistical analysis, as planned. However, four studies
compared scales within the same participant pools, enabling
narrative comparisons to be drawn (Brombo 2018; Hsu 2017;
Kashyap 2014; Richardson 2018).
Respective performance of scales was relatively heterogeneous
across studies. Nevertheless, some patterns were apparent.
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First, while all anticholinergic measurement scales showed an
association with cognitive decline or dementia, the DBI-ach was
consistently the least strongly associated scale, demonstrating
lower odds for future cognitive decline or dementia than all scales it
was compared against in two separate studies (Hsu 2017; Kashyap
2014). The ARS scale showed some of the strongest reported
associations with cognitive decline or dementia when compared
to other scales. Importantly, however, there was evidence that
associations are strongest at lower and higher ARS scores,
suggesting a U-shaped relationship with cognitive decline or
dementia (Hsu 2017). The ADS and ACB scales were on the whole
comparable, demonstrating a similar strength of association in
the two studies that compared them (Kashyap 2014; Richardson
2018). All other available scales described in this review were not
evaluated in tandem with a secondary scale in the same study
population and as such cannot be reliably compared.
D I S C U S S I O N
Summary of main results
Anticholinergic drug use is consistently associated with future
cognitive decline or dementia. Our results suggest that cognitively
unimpaired older adults who use drugs defined as 'definitely'
anticholinergic by the ACB scale may have more than two-times
greater odds of developing future cognitive decline or dementia
than non-users, independent of age, sex, and comorbidities.
Moreover, a relationship between severity of anticholinergic
burden and future dementia appears to be apparent: odds of
developing future cognitive decline or dementia may rise as
extent of anticholinergic burden increases. People with a severe
anticholinergic burden might see their odds of cognitive decline or
dementia increase by as much as 227%.
While our findings are largely based on anticholinergic drugs
as measured by the ACB scale, the association appears to
exist regardless of which anticholinergic scale is used. All
anticholinergic measurement scales evaluated in this review
showed an association with cognitive decline or dementia.
Interestingly, the DBI-ach was consistently less strongly associated
with future cognitive decline or dementia than other scales when
making within-study comparisons. This is contrary to previous
assertions that scales incorporating dosage are more likely to be
reliable risk predictors (Mayer 2015). Of all the available scales, the
evidence suggests the ARS is less well suited to the role of predicting
future cognitive decline or dementia; this is due to an apparent U-
shaped relationship that violates the assumption that severity of
anticholinergic drug scores are additive to the overall risk (at least
until a plateau is reached). This curious trend may be a by-product
of increased prescribing of drugs rated 'less severe' by the ARS scale
as treatments for prodromal symptoms of dementia (Hsu 2017).
At present, the ACB scale is the most popular available
anticholinergic burden measurement tool. Although no
anticholinergic burden scale can be considered the 'gold standard',
there is some justification for the popularity of the ACB scale
in this area. Specifically, it was explicitly designed to evaluate
the association between anticholinergic burden and cognition
(Boustani 2009), and as such considers factors such as the
anticholinergic potency of a drug when assigning an anticholinergic
burden rating. Furthermore, it demonstrates a trend suggesting
a steady increase in risk as severity of anticholinergic burden
increases, as seen both in our meta-analysis and in previous
studies (Pasina 2013); it incorporates the second highest number
of drugs (99) of all available scales (Mayer 2015), and was ranked
the highest quality of 19 available scales in a comprehensive
systematic review (Lisibach 2021), achieving the best score for
'rigour of development.' It is also one of only three available scales
to oFer guidance on use in clinical practice along with clear scoring
rules that allow reproducibility. Limitations of the ACB scale relate
to it not considering dosage, drug interactions, or clearance of
respective drugs – all of which are likely relevant to the evident
risk of future cognitive decline or dementia. Supplementation of
the ACB scale with other existing anticholinergic measurement
systems, such as 'Beers criteria', was an approach adopted by
several studies included in this review. Augmenting the ACB scale
with additional measures may seem like an attractive approach
to enhance ACB scale-based anticholinergic burden measurement;
but, currently there is insuFicient evidence to determine the extent
to which this improves prognostic accuracy compared to when the
ACB scale is used alone.
Overall completeness and applicability of evidence
Most included studies were conducted in older adult populations
in various regions throughout the world. However, there was little
to no representation from Middle Eastern, South American, or
African populations; therefore, we cannot say our results generalise
'globally.' Similarly, included participants were overwhelmingly
from community-based settings and we could not delineate
specific pooled rates for older adults in secondary care settings,
or reliable pooled rates for those attending primary care. People
recruited in primary or secondary care settings likely diFer in
important demographics, including mean age and number of
health conditions, which may increase or reduce the influence
of anticholinergic burden on future risk of cognitive decline or
dementia. As such, our reported rates of increased risk for older
adults are particularly relevant to those in the community.
Our evidence is also restricted to older adults who are 'cognitively
healthy.' Anticholinergic burden may be equally important for
those with an established cognitive syndrome but this was not a
focus of this review.
Certainty of the evidence
Our results are tempered by lack of control for reverse causation,
imprecision in reported eFect size, risk of publication bias, and
the general risk of bias observed throughout included studies.
Consequently, our overall confidence in the evidence for our
primary pooled analysis was low.
If anticholinergic drugs are prescribed as a treatment for prodromal
signs of dementia, such as mood symptoms or sleep disorders,
any risk association will be inflated as a consequence. Similarly, if
symptoms and subsequent prescriptions increase right up to the
point of the dementia diagnosis, the observed trend of increasing
risk based on severity of anticholinergic burden could simply reflect
this. While it is not known what lag time is suFicient to reduce
protopathic bias (i.e. risk of reverse causation), when we restricted
pooled rates to those studies that had at least a two-year lag-time
and not thought to be at high risk of bias overall, the association
between anticholinergic drug use and dementia remained. This
runs contrary to the reverse causation hypothesis and provides
some reassurance that the observed eFects are related to the
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anticholinergic properties of the drugs themselves. Regardless, our
pooled rates are likely an overestimation.
Limitations of the review process
To minimise bias in the review process, two review authors
independently screened all titles, extracted data, and conducted
risk of bias assessment. Despite this, we encountered several
issues.
Tools that were used throughout our review were not explicitly
designed for use with prognostic research. To mitigate this
problem, we followed best available guidelines to adapt GRADE for
evaluation of prognostic study evidence and enhanced QUIPS by
incorporating specific guidance when rating each category.
We evaluated cognition and dementia as a composite variable since
both are important to older adults and combining these outcomes
increases power to detect smaller, but still clinically meaningful
prognostic associations. Despite this, our meta-analyses were
limited by power constraints. One recurring issue was the tendency
of authors to report ORs subgrouped into low, moderate, and high
user categories and compare against a common reference standard
(non-users). As a consequence, we were required to select single
ORs from a specific subgroup for each analysis. Although we were
able to extract relevant data from many of the included studies, we
received a poor response from authors who we contacted about
providing additional data, further reducing the strength of our
analyses. In combination, these issues challenge the veracity of
our results – particularly our subgroup analyses. For instance, our
quantification of the association between low, moderate, and high
anticholinergic burden and future cognitive decline or dementia
are derived from just three studies, thus are of questionable
validity.
We were also unable to conduct a number of analyses that
we prespecified in our protocol due to issues with the types
of data that were presented in available studies (Quinn 2020).
Specifically, we could not pool linear or hazard ratio outcome data,
investigate the association between anticholinergic burden and
duration of exposure, or determine if number of comorbidities or
polypharmacy were sources of the high heterogeneity in observed
eFect sizes between studies.
Lastly, we did not include grey literature in our review. Although we
were unable to formally assess for publication bias, we identified
few small studies that reported an absence of association between
the ACB scale and dementia. Existent studies that did report a
lack of association typically reported a significant association with
another form of cognitive impairment (e.g. MCI) (Whalley 2012);
hence, there is a real risk of publication bias in this field.
Agreements and disagreements with other studies or
reviews
Our results are broadly consistent with three previous meta-
analyses (Dmochowski 2021; Pieper 2020; Ruxton 2015). These
prior reviews report a 20% to 46% increased risk for dementia
(Dmochowski 2021; Pieper 2020), and a 45% increased risk for
cognitive impairment (Ruxton 2015). This is lower than our primary
pooled rates but in line with our analysis restricted to studies at
lower risk of bias, which may be more accurate. Our findings also
build upon these previous meta-analyses by quantifying risk of ACB
scale measured drugs specifically, along with risks for each ACB
scale subgroup (low, moderate, high).
The increasing risk based on extent of anticholinergic burden
is consistent with prior evidence: Joung 2019 found people
on moderate-to-high dosages of anticholinergic drugs were at
significantly greater risk of Alzheimer's disease than people on very
low dosages, while Coupland 2019 similarly found a dose-response
eFect. Low anticholinergic burden represents the most common
category that those with any form of anticholinergic burden reside,
and although we observed a significant association with dementia
at this level, it remains a point of contention due to frequent
negative findings within the literature (Hafdi 2020).
Lastly, previous studies have suggested that the cholinergic system
may play a particular role in episodic memory (Bentley 2011).
It has been theorised that any impact of anticholinergic drugs
may be largely confined to this domain (Papenberg 2017). We
found considerable variability throughout the literature regarding
reported cognitive domains aFected by anticholinergic drug use.
As such, our results do not support this theory and the available
evidence suggests that disruption of the cholinergic system leads
to widespread cognitive impairment.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Clinicians should think carefully about the need to prescribe
anticholinergic drugs to older adults. Estimates suggest as many
as 20% to 50% of older people are prescribed at least one
anticholinergic medication (Fox 2014). If the observed link between
anticholinergic drug use and future dementia is causal, these
exposure rates imply anticholinergics meaningfully contribute to
the global dementia burden; albeit the extent of this contribution
is diFicult to determine due to the risk of bias present within
studies. Moreover, there are associations with increased risk of
mortality (Grave-Morris 2020), impaired physical function, and
reduced quality of life (Stewart 2020), emphasising the potential
dangers anticholinergic drugs pose to older adults.
While we would advise caution in prescribing anticholinergic drugs,
we cannot comment on the potential benefits of deprescribing for
people already receiving anticholinergic drugs. It is uncertain to
what extent any adverse eFects of anticholinergic medicines are
reversible upon cessation. One randomised controlled trial (RCT)
provided no evidence that deprescribing can benefit cognition
(Kersten 2013), albeit this RCT was underpowered and focused
only on short-term cognitive changes (Pieper 2020). We can also
hypothesise from observational studies that circumstances may
exist in which the increased risk of dementia associated with use
of anticholinergic drugs is irreversible. For example, risk of future
dementia for older adults with high anticholinergic burden has
been found to be unaltered by recency of use: those who are historic
heavy users of anticholinergic drugs might be at similar risk to
recent or even long-term continuous heavy users (Gray 2015).
Implications for research
Several outstanding issues remain to be resolved. Most
prominently, clarification is needed regarding the importance
of medication type on the association between anticholinergic
burden and risk of future cognitive decline or dementia. Although
plausible mechanisms exist by which anticholinergic drugs
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may impact the cognition of older adults (Shah 2013), some
studies only observed significant associations for certain types of
anticholinergic drugs, many of which are prescribed for prodromal
symptoms of dementia. While this variability based on drug-type
was not consistent across studies, there remains a possibility that
anticholinergic eFects may not be driving the observed association.
It is likely that the only way a causal role for anticholinergic drugs
and risk of future cognitive decline or dementia can be conclusively
established (or disregarded) is via an RCT in which some people
have their anticholinergic medications stopped to determine if the
risk of future cognitive decline or dementia is reduced.
We likewise do not know precise details regarding the interaction
between severity of anticholinergic burden, duration of exposure,
and the frequency of use required to cause long-term harm.
If anticholinergic drugs play a causal role, establishing the
relationship between these variables could be key to our ability to
alter future dementia risk. As such, this is a crucial avenue for future
research.
Methodological standards also require improvement. Authors
should be sure to register protocols before conducting their study.
This is necessary to determine the extent of publication bias within
the field as well as adequately evaluate statistical approaches. Drug
use measurement is currently extremely limited. Reported study
methods are typically not suFicient to reliably establish dosage
or adherence, and total exposure period is oKen inadequately
reported. Use of anticholinergic drugs can vary over the course
of a study (Shah 2013), which is likely to have a bearing on
results, yet not all studies take measurements at multiple time
points. Researchers should also ensure that those who ascribe
anticholinergic ratings are blinded to cognitive outcomes (and
vice versa) to minimise bias, and ensure inclusion of psychiatric
conditions when controlling for comorbidities. Addressing these
limitations would go some way to improving our understanding
of the relationship between anticholinergic burden and risk of
cognitive decline or dementia.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Design: retrospective cohort
Setting: primary care
Country: France
Duration of follow-up: 1 year
Covariates controlled for: age, sex, education, untreated depression, and treated hypertension
Participants Participants numbers: 372
Population type: older adults
Sex: not clear
Age (mean): not stated
Prognostic factors Anticholinergic burden measurement method: combined rating of drugs' serum radioreceptor assay
and mean estimated clinical effects, established via literature review
Outcomes Outcomes assessed: MCI; dementia; cognitive decline
Outcome ascertainment dementia/MCI: independent clinical assessment via expert
Outcome ascertainment cognitive decline: computerised neuropsychometric examination
Diagnostic criteria dementia: DSM-III criteria for neurogeriatric disorder
Diagnostic criteria MCI: revised criteria proposed by the Stockholm consensus group
Diagnostic criteria cognitive decline: scores on cognitive testing




Item Authors' judgement Support for judgement
Ancelin 2006 
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Cochrane Database of Systematic Reviews
Study participation Unclear Poor reporting of comorbidities.
Study attrition Unclear Only 80% followed up. No analysis carried out to evaluate if participants with
missing data differed in baseline anticholinergic burden score compared to
participants with full data.
Prognostic factor mea-
surement
Unclear Repeated measurements of drug use at 1 year. Used self-report to establish
prescribed and non-prescribed medication use. Had second method of estab-
lishing drugs (checking with GP). No mention of recording dosage, frequency,
or adherence.
Outcome measurement Unclear No blinding but anticholinergic burden scores assigned after cognitive diagno-
sis.
Study confounding Unclear Controlled for age, sex, and comorbidities that covered both physical and psy-
chiatric conditions, but only controlled for 2 comorbidities.
Reverse causation No No mention of restricting anticholinergic drug use to 1 year before MCI onset.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: secondary care
Country: Italy
Duration of follow-up: 1 year
Covariates controlled for: age, sex, education, smoking, hypertension, coronary heart disease, renal
failure, anaemia, infectious diseases, and ARS score at first follow-up
Participants Participants numbers: 1123
Population type: older adults
Sex: 56% women (629)
Age (mean): 81 years
Prognostic factors Anticholinergic burden measurement method: ACB scale; ARS scale
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment: MMSE
Diagnostic criteria: cognitive decline: scores on cognitive testing
Source of funding Italian Ministry of Labour, Health and Social Policy
Notes  
Brombo 2018 
Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive
syndrome (Review)
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Item Authors' judgement Support for judgement
Study participation No Baseline dementia prevalence was 20%.
Study attrition No Cognition of follow-up data only available for 53.6% of baseline sample.
Prognostic factor mea-
surement
Unclear Medication use established via questionnaire only.
Outcome measurement Unclear No blinding but anticholinergic burden likely assessed after cognitive score es-
tablished.
Study confounding Unclear Age, sex, and comorbidities (including physical and depression) all measured;
however, did not control for depression in regression analysis.
Reverse causation No No restriction to anticholinergic burden measurement (assessed at 12 months
before and 9 months before).
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: primary care
Country: USA
Duration of follow-up: 1 year
Covariates controlled for: age, sex, race, arthritis, cancer, CAD, CHF, COPD, diabetes, liver disease, renal
disease, stroke, number of non-anticholinergic drugs, prior inpatient admissions, prior ED visits, prior
outpatient visits
Participants Participants numbers: 3344
Population type: older adults
Sex: 71% women (2374)
Age (mean): 71 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: dementia + MCI
Outcome ascertainment dementia/MCI: consensus diagnosis based on multidisciplinary evaluation
Diagnostic criteria dementia/MCI: DSM-III criteria
Source of funding Not stated
Campbell 2016 
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Notes  
 
Item Authors' judgement Support for judgement
Study participation No Describes age, sex, and comorbidities of population. However, almost all had
hypertension (99%, which was not reported in this study but in Cai 2013, which
uses the same data source) and high prevalence of stroke and other cardiovas-
cular conditions so population may not be very generalisable.
Study attrition No No tests of missing data.
Prognostic factor mea-
surement
Unclear Only 1 method used to determine medications.
Outcome measurement Unclear No blinding but anticholinergic burden likely assessed after cognitive assess-
ment.
Study confounding Unclear Controls for age, sex, and comorbidities, but comorbidities did not cover psy-
chiatric domain.
Reverse causation No Anticholinergic burden measurement was collected over the 12 months before
cognitive evaluation. Does not mention restricting to anticholinergic drugs
that were prescribed only 12 months before cognitive assessment.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: USA
Duration of follow-up: 11 years
Covariates controlled for: sex, race, birth year (age), years of education, follow-up time, smoking status
(current, former, never), drinker (never, ever), number of cardiovascular comorbidities
Participants Participants numbers: 723
Population type: older adults
Sex: 31% women (226)
Age (mean): 52 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: Alzheimer's disease + MCI
Outcome ascertainment dementia/MCI: consensus diagnosis based on multidisciplinary evaluation
Chuang 2017 
Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive
syndrome (Review)
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Diagnostic criteria for dementia and Alzheimer's disease: DSM-III
and NINCDS-ADRDA criteria
Diagnostic criteria for MCI: Petersen's criteria
Source of funding Intramural Research Program, National Institute on Aging, and National Institutes of Health
Notes  
 
Item Authors' judgement Support for judgement
Study participation Unclear Demographics and comorbidities all reported; however, population was ma-
jority male (69%) with low mean age (52 years).
Study attrition No Less than a third of baseline sample remaining for inclusion in analysis.
Prognostic factor mea-
surement
Unclear Patients brought unused medications to visit. Cross-checked by study nurses
but no measurement of dosage or frequency of use. Repeated measurements
made at each visit.
Outcome measurement Unclear No blinding but using data obtained from previously conducted longitudinal
cohort study so anticholinergic burden likely measured after cognitive assess-
ment already complete.
Study confounding Unclear Comorbidities controlled for did not include psychiatric conditions.
Reverse causation No No restriction mentioned on anticholinergic drug use time frame before cogni-
tive assessment and information on duration of use only available for 49% of
participants.
Statistical analysis and re-
porting





Methods Design: retrospective case-control
Setting: community
Country: UK
Duration of follow-up: 11 years
Covariates controlled for: BMI, smoking status, alcohol consumption, Townsend deprivation score, eth-
nic group, coronary heart disease, atrial fibrillation, heart failure, hypertension, hyperlipidaemia, di-
abetes (type 1 and type 2), stroke, transient ischaemic attack, subarachnoid haemorrhage, renal dis-
ease, asthma, COPD, anxiety, depression, bipolar disorder, schizophrenia, severe head injury, cognitive
decline/memory loss, antihypertensive drugs, aspirin, hypnotics, anxiolytic drugs, non-steroidal an-
ti-inflammatory drugs. Cases and controls were matched for age (within 1 year), sex, general practice,
and calendar time.
Participants Participants numbers: 284,343
Coupland 2019 
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Population type: older adults
Sex: 63% women (179,420)
Age (mean): 82 years
Prognostic factors Anticholinergic burden measurement method: ACB scale and Beers criteria
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: clinical codes recorded in official records
Diagnostic criteria for dementia: not stated
Source of funding National Institute for Health Research School for Primary Care Research
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Age, sex, and comorbidities all described.
Study attrition Unclear No comparison of missing values with anticholinergic burden.
Prognostic factor mea-
surement
Unclear Relied on prescriptions for establishing medications.
Outcome measurement Unclear Relied on database diagnosis.
Study confounding Yes Cases and controls were matched for age and sex; comorbidities controlled for
in regression analysis and covered physical and psychiatric domains.
Reverse causation Yes Restricted medications to 12 months, 3 and 5 years before diagnosis.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: UK
Duration of follow-up: 2 years
Covariates controlled for: age, sex, baseline MMSE, education, social class, number of non-anticholiner-
gic medications, and number of comorbidities
Participants Participants numbers: 12,423
Population type: older adults
Fox 2011a 
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Sex: 60% women (7417)
Age (mean): not stated
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment cognitive decline: MMSE
Diagnostic criteria for cognitive decline: scores on cognitive testing
Source of funding Medical Research Council, UK
Notes  
 
Item Authors' judgement Support for judgement
Study participation Unclear Lack of detail in reporting exclusion criteria.
Did not state numbers with baseline dementia.




Yes Used self-report cross-checked by counting remaining medications. Recorded
dosage, frequency, and quantity.
Outcome measurement Unclear No blinding to outcome but anticholinergic burden likely established after
cognitive assessment.
Study confounding Unclear Age, sex, and comorbidities all measured (comorbidities included both physi-
cal and psychiatric).
However, controls for 'number of health conditions' rather than each condi-
tion individually.
Reverse causation Unclear Restricted analysis to anticholinergic burden baseline association with change
in MMSE score at 2 years.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: USA
Duration of follow-up (mean): 7.3 years
Gray 2015 
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Covariates controlled for: ACT cohort, age, age at ACT study entry, sex, education, BMI, current smok-
ing, regular exercise, self-rated health, hypertension, diabetes, stroke, coronary heart disease, Parkin-
son's disease, history of depressive symptoms, and current benzodiazepine use
Participants Participants numbers: 3434
Population type: older adults
Sex: 60% women (20,470)
Age (mean): 74 years
Prognostic factors Anticholinergic burden measurement method: Beers criteria combined with a literature review
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: consensus diagnosis based on multidisciplinary evaluation
Diagnostic criteria dementia: DMS-IV and NINCDS-ADRDA criteria
Source of funding National Institute on Aging, NIH Grants, and the Branta Foundation
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Random community sampling and reports age, sex, and comorbidities.
Study attrition Unclear Conducted series of sensitivity analyses but did not assess for differences in
missing and anticholinergic burden score.
Prognostic factor mea-
surement
Unclear Relied on pharmacy dispensing data. Updated exposure as participants were
followed forward in time.
Outcome measurement Unclear No blinding to outcome but anticholinergic burden likely measured after cog-
nitive assessment.
Study confounding Yes Controlled for age, sex, and comorbidities.
Reverse causation Unclear Excluded prescriptions in the most recent 1-year period.
Statistical analysis and re-
porting






Methods Design: retrospective cohort
Setting: community
Country: UK
Duration of follow-up: 10 years
Grossi 2019 
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Covariates controlled for: sex, age, education, social class, residential accommodation, centre of re-
cruitment, study arm, health conditions at year 0 or year 2 (stroke, Parkinson's disease, epilepsy, sleep
problems, anxiety, depression), self-reported health at year 2, disability at year 2, MMSE at year 2,
MMSE orientation subscore at year 2, decrease in MMSE score between year 0 and year 2, and self-per-
ceived change in memory function between year 0 and year 2.
Participants Participants numbers: 8216
Population type: older adults
Sex: about 69% women (5669)
Age (mean): 74 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: computer-assisted algorithm
Diagnostic criteria dementia: AGECAT scores ≥ 3 (which is equivalent to dementia as diagnosed by DSM-
III-R)
Source of funding UK Alzheimer's Society
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Reported age, sex, and comorbidities.
Study attrition No Major loss to follow-up.
Prognostic factor mea-
surement
Unclear Self-report only. No measurement of dosage, frequency of use, or adherence.
Anticholinergic burden measurement repeated at each interview (year 0 and
year 2).
Outcome measurement Unclear No blinding but seemed like anticholinergic burden likely assigned after de-
mentia diagnosis ascertained.
Study confounding Yes Age, sex, and relevant comorbidities all controlled for.
Reverse causation Yes Anticholinergic burden measurement taken 8 years before dementia diagnosis
and those who developed dementia at year 2 (2 years after anticholinergic bur-
den use was first measured) were excluded.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Hafdi 2020 
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Country: Netherlands
Duration of follow-up (mean): 6.7 years
Covariates controlled for: age, sex, history of cardiovascular disease or stroke (or both), education,
MMSE at baseline, and Geriatric Depression Scale at baseline
Participants Participants numbers: 3526
Population type: older adults
Sex: 54% women (1919)
Age (mean): 74 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: consensus diagnosis based on multidisciplinary evaluation
Diagnostic criteria dementia: DSM-IV
Source of funding Dutch Ministry of Health, Welfare and Sport; the Dutch Innovation Fund of Collaborative Health In-
surances; and the Netherlands Organisation for Health Research and Development
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Reported age, sex, and comorbidities. Minor issue with slightly restricted age
population.
Study attrition Unclear No comparison between completers vs non-completers/missing data.
Prognostic factor mea-
surement
Unclear 2 methods (self-report cross-checked with electronic records). Repeated mea-
surement at 2 years – though only once and this study ran for 8 years; no men-
tion of whether anticholinergic scores changed and lack of detail on the ques-
tion so could not be certain if asked about non-prescribed drugs. No measure
of adherence or dosage. On basis of these issues assigned unclear risk of bias.
Outcome measurement Unclear No blinding but anticholinergic burden assignment conducted after cognitive
diagnosis established.
Study confounding Yes Age, sex, and comorbidities all measured.
Reverse causation Unclear Anticholinergic burden measurement taken 2 years before dementia assess-
ment and excluded those who developed dementia in first 2 years after taking
anticholinergics.
Statistical analysis and re-
porting
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Study characteristics
Methods Design: retrospective cohort
Setting: community
Country: USA
Duration of follow-up: 1 year
Covariates controlled for: age, education, race, living arrangement, before enrolment. history of alco-
hol use and smoking, and depressive symptoms, ADL function, Charlson Comorbidity Index
Participants Participants numbers: 544
Population type: older adults
Sex: 100% men
Age (mean): 74 years
Prognostic factors Anticholinergic burden measurement method: clinician-rated
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment cognitive decline: HVRT, IADL
Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding Claude D. Pepper Older Americans Independence Center at Yale University School of Medicine
Notes  
 
Item Authors' judgement Support for judgement
Study participation No Men only with hypertension.
Study attrition Unclear Attrition was high but just below the 20% high risk mark. Conducted analysis
to investigate potential impact of missing values on final model and did not al-
ter conclusions but did not explain what these missing data analyses entailed.
Prognostic factor mea-
surement
Unclear No measurement of dosage or frequency of use. No measurement of non-VA
sources of drugs. Conducted repeated measurements over the follow-up peri-
od for the 12 months preceding each assessment at 1 and 2 years.
Outcome measurement Unclear No mention of blinding. Unclear if anticholinergic burden was applied before
or after cognitive assessment score was determined.
Study confounding Yes Only men in sample so no sex. Controlled for comorbidities via Charlson Co-
morbidity Index along with depression.
Reverse causation No Anticholinergic burden exposure time frame defined as the 12 months preced-
ing each follow-up at 1 year and 2 years. (so seems to have covered medication
use right up to the point of each follow-up assessment).
Statistical analysis and re-
porting
Unclear No assessment of assumptions. Referred to a protocol but was not a protocol
specifically for this study so no mention of an analysis plan.
Han 2008 
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Methods Design: retrospective cohort
Setting: community
Country: Taiwan
Duration of follow-up: 10 years
Covariates controlled for: sex and time-varying comorbidities. ARS and ACB scales were further adjust-
ed for defined daily dose of drugs with anticholinergic properties (age controlled for by subgrouping)
Participants Participants numbers: 116,043
Population type: older adults
Sex: 50% women (57,552)
Age (mean): not stated
Prognostic factors Anticholinergic burden measurement method: ARS scale; ACB scale; DBI-ach scale
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: clinical codes recorded in health records
Diagnostic criteria dementia: not stated
Source of funding Ministry of Science and Technology
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Reported age, sex, and covariates. Random sampling of population contained
in a national insurance database registry.
Study attrition Unclear No mention of missing data. No mention of mortality over 10-year follow-up or
how dealt with this.
Prognostic factor mea-
surement
Unclear Only 1 method (prescription records) employed for determining medications.
Anticholinergic burden assessed monthly for 120 months.
Outcome measurement Unclear Relied on medical record diagnoses.
Study confounding Unclear Controlled for most relevant variables including comorbidities (used Charlson
Comorbidity Index). Age not controlled for in the model but categorised peo-
ple into distinct age groups and conducted 3 analyses on that basis.
No psychiatric domains assessed.
Reverse causation No No mention of restricting anticholinergic burden measurement other than re-
moving people with dementia at baseline (1 year after enrolment). Anticholin-
ergic burden was measured monthly over the 10-year time frame so appeared
Hsu 2017 
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that beyond the initial 1 year following study enrolment, anticholinergic drug
use could be at risk of being prescribed for prodromal dementia symptom.
Statistical analysis and re-
porting





Methods Design: prospective cohort
Setting: secondary care
Country: USA
Duration of follow-up: 1 year
Covariates controlled for: age, BMI, time, group, GDS, total number of medications, neurological diag-
nosis
Participants Participants numbers: 106
Population type: overactive bladder population
Sex: 100% women
Age (mean): 77 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment cognitive decline: MoCA
Diagnostic criteria cognitive decline: change in scores on cognitive testing
Source of funding None.
Notes  
 
Item Authors' judgement Support for judgement
Study participation No Women only. Overactive bladder population.
Study attrition No Considerable attrition.
Prognostic factor mea-
surement
Unclear Only 1 method employed (ACB scale). No mention of assessing non-prescrip-
tion anticholinergic medications.
Outcome measurement No No mention of blinding and not a retrospective design so knowledge of anti-
cholinergic use may have biased MoCA scoring. Repeated MoCA-based testing
could also induce practice effects, masking any cognitive decline.
Study confounding Yes Age and comorbidities controlled for.
Iyer 2020 
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Reverse causation No No restrictions placed on ACB use before follow-up assessments up to 12
months.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: Germany
Duration of follow-up (mean): 4.5 years
Covariates controlled for: sex, age, level of education, depression, ApoE genotype
Participants Participants numbers: 2605
Population type: older adults
Sex: 65% women (1701)
Age (mean): 79 years
Prognostic factors Anticholinergic burden measurement method: Chew list
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: consensus diagnosis based on multidisciplinary evaluation
Diagnostic criteria dementia: DSM-IV and ICD-10 criteria




Item Authors' judgement Support for judgement
Study participation Unclear Random sampling of GP registries. > 50% participation rate. No reporting of
comorbidities (other than depression and ApoE) so scored as moderate.
Study attrition Unclear No mention of missing data or attrition (despite extensive follow-up period).
In original study that they used data from, the baseline cohort was 3327; how-




Unclear Lack of detail regarding how medication use was established. Repeated mea-
surements of anticholinergic use at each 8-month follow-ups.
Jessen 2010 
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Outcome measurement Unclear No blinding but seemed likely that anticholinergic burden score was assigned
retrospectively after cognitive diagnosis was established in earlier study.
Study confounding No Did not control for comorbidities other than depression and ApoE genotype.
Reverse causation No No restriction on anticholinergic burden time frame measurement reported.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: South Korea
Duration of follow-up: 10 years
Covariates controlled for: age, sex, level of income, diabetes mellitus, hypertension, myocardial infarc-
tion, cardiovascular diseases, dizziness, genitourinary diseases, epilepsy, Parkinson's disease, neural-
gia, skin disease, sleep disorder, prescribed doses of weak anticholinergics, and cumulative prescribed
days of other non-anticholinergic agents that could impair cognitive function (all psychotic diseases
including depression, psychosis, and anxiety were excluded in the step of participant selection in ad-
vance).
Participants Participants numbers: 191,805
Population type: older adults
Sex: 55% women (105,493)
Age (mean): 67 years
Prognostic factors Anticholinergic burden measurement method: ACB scale plus Beers criteria
Outcomes Outcomes assessed: Alzheimer's disease
Outcome ascertainment dementia: clinical codes recorded in medical records
Diagnostic criteria dementia: ICD-10: F00 or G30) and a prescription for anti-Alzheimer's disease agents
(i.e. donepezil, rivastigmine, galantamine, or memantine)
Source of funding Not stated
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Population-based study with adequate reporting of demographics and comor-
bidities.
Joung 2019 
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Study attrition Unclear No mention of missing data.
Prognostic factor mea-
surement
Unclear Relied on prescription records. Exposure measurement taken throughout fol-
low-up.
Outcome measurement Unclear Relied on medical record diagnoses.
Study confounding Yes All appropriate variables controlled for. Depression controlled for via exclusion
of antidepressant use in sensitivity analysis only.
Reverse causation Yes Restricted to dementia onset 2 years after baseline anticholinergic use. Also
various statistical analysis to control for protopathic bias (reverse causation)
did not change results so scored as low risk of bias on this basis.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: Canada
Duration of follow-up: 1 year
Covariates controlled for: None.
Participants Participants numbers: 102
Population type: older adults
Sex: 84% women (86)
Age (mean): 72 years
Prognostic factors Anticholinergic burden measurement method: DBI-ach scale; ACB scale; ADS scale; ARS scale
Outcomes Outcomes assessed: MCI; cognitive decline
Outcome ascertainment MCI: independent clinical assessment via expert
Outcome ascertainment cognitive decline: neuropsychological tests and an MoCA
Diagnostic criteria MCI: DSM-5 criteria for a mild neurocognitive disorder.
Diagnostic criteria cognitive decline: 3 different ways: worsening in the raw neuropsychological test
scores for each test; a change in scores on each test that exceeded an expected cut-oF based on the
test–retest reliable change index; and a change in scores on each test that persisted when regression to
the mean, practice effects, and age were accounted for using the standardised regression-based mea-
sure method
Source of funding Canadian Institutes of Health Research
Notes  
Kashyap 2014 
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Item Authors' judgement Support for judgement
Study participation Unclear Report on age and sex but did not report which comorbidities they measured.
Study attrition Unclear No comparison with missing data. Did not describe the proportion or potential
impact of loss to follow-up.
Prognostic factor mea-
surement
Yes Established by patient self-report. Validated by nurse checking medication
box. Recorded frequency, adherence, and dosage.
Outcome measurement Unclear There was blinding to the mild neurocognitive disorder diagnosis but not to
the change in cognition evaluation; retrospective anticholinergic burden de-
termination.
Study confounding No Only conducted univariate analysis. No confounders adjusted for.
Reverse causation No No time restriction on anticholinergic burden measurement (anticholinergic
burden measured at baseline then again at 12 months – combined measures
and used 'increase in anticholinergic burden' as the independent variable.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: USA
Duration of follow-up: 4.9 years
Covariates controlled for: age, race, education, smoking, physical activity, modified Charlson Comor-
bidity Index, and baseline MMSE score
Participants Participants numbers: 1429
Population type: older adults
Sex: 100% women (1429)
Age (mean): 83 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment cognitive decline: battery of 7 cognitive tests
Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding National Institute of Aging at the National Institutes of Health and the Alzheimer's Association
Koyama 2014 
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Notes  
 
Item Authors' judgement Support for judgement
Study participation No Women only.
Study attrition No Final sample was 1429/4606 at baseline.
Prognostic factor mea-
surement
No Participants asked to bring in all medication used in 30 days prior to baseline
visit. No measurement of dosage or frequency of use. No subsequent measure-
ment of medication use despite 5-year follow-up.
Outcome measurement Unclear No blinding but cognitive assessment results likely defined before anticholin-
ergic burden calculated.
Study confounding Unclear Controlled for comorbidities via a modified Charlson Comorbidity Index; how-
ever, no depression controlled for.
Reverse causation Unclear Anticholinergic drug use at baseline only and follow-up was at 2 years. Howev-
er, no exclusion around dementia at baseline or 1 year reported.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: Australia
Duration of follow-up: 4 years
Covariates controlled for: age, gender, education, depression, and self-rated health
Participants Participants numbers: 2058
Population type: 'young old'
Sex: 48% women (992)
Age (mean): 62 years
Prognostic factors Anticholinergic burden measurement method: ADS scale
Outcomes Outcomes assessed: cognitive decline; MCI
Outcome ascertainment MCI: independent clinical assessment via expert
Outcome ascertainment cognitive decline: a neuropsychological assessment
Diagnostic criteria MCI: Jack 1999 criteria
Low 2009 
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Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding National Health and Medical Research Council grants
Notes  
 
Item Authors' judgement Support for judgement
Study participation Unclear Sample was restricted to 'young old' (aged 60–64 years) and had high mean
education (14 years).
Study attrition Unclear 87% of participants followed up. Comparison of lost to follow-up vs followed
up participants conducted but showed people lost to follow-up were more
likely to be on anticholinergic medicine.
Prognostic factor mea-
surement
Unclear Anticholinergic drug use reported at baseline and 4-year follow-up.
Used self-reported medication use but only 1 method employed. No measure-
ment of frequency, duration, or dose.
Outcome measurement No No blinding to anticholinergic burden during clinical diagnosis, but anticholin-
ergic burden likely measured retrospectively. MCI was defined according to
dated criteria (Jack 1999 rather than Peterson). MMSE used to assess cognition
but study had high education mean and displays a ceiling effect.
Study confounding Unclear Controlled for age, sex, and comorbidities that cover both physical and psychi-
atric domains. However, minimal comorbidities.
Reverse causation No Excluded people with dementia at baseline but did not seem to be any formal
restriction in anticholinergic drug use and time of outcome assessment at 4
years.
Statistical analysis and re-
porting
No No protocol and no assumptions checked. Also analysis for MCI outcome was





Methods Design: retrospective cohort
Setting: community
Country: Ireland
Duration of follow-up: 2 years
Covariates controlled for: baseline wave (i.e. whether the period was wave 1–2 or 2–3), age at baseline
wave, sex, education, marital status, employment, incontinence, quintiles of CES-D score, pain, trouble
falling asleep, disabilities, smoker, vision, hearing, self-reported doctor-diagnosed conditions, eye con-
ditions, cardiovascular conditions (listed in paper supplementary materials), other health conditions
(listed in paper supplementary materials)
Participants Participants numbers: 7027
Population type: older adults
Moriarty 2020 
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Sex: 55.6% women (3906)
Age (median): 61 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment cognitive decline: 3 cognitive tests (MMSE, animal naming, assessment of re-
call)
Diagnostic criteria cognitive decline: scores on cognitive testing




Item Authors' judgement Support for judgement
Study participation Unclear Relatively young participant pool.
Study attrition Yes Minimal attrition (7027 included out of 8504 total study sample)
Prognostic factor mea-
surement
Unclear Assessed via 2 methods but duration and dosage only recorded for a subset of
participants and adherence not recorded.
Outcome measurement Unclear No blinding to cognitive assessment mentioned but ACB scores likely applied
after cognition scores derived.
Study confounding Yes All essential covariates adjusted for including psychiatric conditions.
Reverse causation Unclear Most people had ≥ 2 years between medication assessment and outcome as-
sessment; however, time frame for new users not restricted so some risk of
protopathic bias.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: Sweden
Duration of follow-up: 6 years
Covariates controlled for: age, sex, education, CRFs, cardiovascular disease, physical inactivity, total
number of drugs, and depression
Participants Participants numbers: 1473
Papenberg 2017 
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Population type: older adults
Sex: 61% women (902)
Age (mean): 70 years
Prognostic factors Anticholinergic burden measurement method: Anatomical Therapeutic Chemical classification system
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment cognitive decline: cognitive test battery
Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding Ministry of Health and Social Affairs
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Age, sex, and comorbidities all reported adequately. Random selection of
community.




Unclear Patients asked to bring in medications they were taking(including non-pre-
scription medications); medical records checked if participant could not pro-
vide information. No mention of recording dosage, frequency, or adherence.
Outcome measurement Unclear No blinding but cognition recorded after cognitive assessment.
Study confounding Yes All relevant comorbidities controlled for.
Reverse causation No No restriction to time frame of anticholinergic drug use mentioned.
Statistical analysis and re-
porting





Methods Design: retrospective case-control
Setting: community
Country: UK
Duration of follow-up: 4 years
Covariates controlled for: age, region, any falls, any fractures, number of doctor consultations in the
12 months before the drug exposure period, number of prescriptions during the drug exposure peri-
od, BMI, smoking status, harmful alcohol use, depression duration, cardiovascular or cerebrovascular
and related diagnoses, mental health diagnoses, other comorbidities. Cases and controls matched on
Richardson 2018 
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sex, year of birth (within 3 years), years of 'up to standard' data history, and area level deprivation mea-
sured by the index of multiple deprivation quintile of each practice based on its postcode.
Participants Participants numbers: 324,703
Population type: older adults
Sex: 63% women (204,563)
Age (mean): 83 years
Prognostic factors Anticholinergic burden measurement method: ACB scale; ADS scale
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: clinical codes recorded in medical records or prescription for a cog-
nitive enhancer
Diagnostic criteria dementia: not stated
Source of funding Alzheimer's Society
Notes  
 
Item Authors' judgement Support for judgement
Study participation Yes Reported age, sex, and comorbidities. All seemed generalisable.
Study attrition Unclear Conducted several sensitivity analyses based on missing data and outcomes,
but did not compare missing data with anticholinergic burden scores.
Prognostic factor mea-
surement
Unclear Only used prescribing records to establish current drug use.
Outcome measurement Unclear Relied on database diagnosis.
Study confounding Yes Controlled for a vast number of covariates including psychiatric and physical
conditions.
Reverse causation Yes Restricted measurement of anticholinergic drug use to ≥ 4 years before index
date for dementia diagnosis.
Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: secondary care
Country: USA
Duration of follow-up: 32 months
Risacher 2016 
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Covariates controlled for: age, sex, total number of medications, cardiac surgery, total number of co-
morbid conditions, other psychiatric conditions and amyloid-β positivity
Participants Participants numbers: 402
Population type: older adults
Sex: 53% women (213)
Age (mean): 73 years
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: dementia and MCI; cognitive decline
Outcome ascertainment dementia/MCI/cognitive decline: comprehensive cognitive and clinical battery
Diagnostic criteria dementia/MCI: not stated
Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding ADNI and Department of Defense ADNI
Notes  
 
Item Authors' judgement Support for judgement
Study participation No High numbers of participants with subjective cognitive decline.
Study attrition Unclear No analysis carried out to evaluate if participants with missing data differed in
baseline anticholinergic burden score compared to those with full data.
Prognostic factor mea-
surement
No Relied on self-report data (according to discussion) for medication use. Not
clear if there were multiple measurements but seems to only be based on
baseline use and follow-up was for several years.
Outcome measurement Unclear No blinding. Is unclear how Alzheimer's disease and MCI were diagnosed in the
study.
Study confounding Unclear Age, sex, and relevant comorbidities all controlled for.
Reverse causation No There were dementia/MCI converters in first 6 and 12 months (figure 4) and no
mention of any exclusions of these participants from analysis.
Statistical analysis and re-
porting
No Checks assumptions. No protocol. Only 58 odd cases of dementia so seemed
underpowered based on number of covariates they claimed to have controlled
for (which seemed to differ in the methods section vs in the results table). Did
not control for depression in analysis despite this differing between anticholin-





Methods Design: retrospective cohort
Shah 2013 
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Setting: community
Country: USA
Duration of follow-up: 10 years
Covariates controlled for: age, gender, and education. For incident users only in a secondary analysis:
ApoE e4 allele, MCI, number of chronic medical conditions, urinary incontinence, number of depressive
symptoms, physical activity, and disability on the Katz Index
Participants Participants numbers: 895
Population type: older adult priests and nuns
Sex: 70% women (623)
Age (mean): 74 years (never users); 75.9 years (incident users); 76.5 years (prevalent users)
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: cognitive decline
Outcome ascertainment cognitive decline: battery of 19 cognitive function tests was administered in
addition to the MMSE
Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding American Philosophical Society, the National Institute on Aging grants, and by the Illinois Department
of Public Health to DAB
Notes  
 
Item Authors' judgement Support for judgement
Study participation No Sample restricted to priests and nuns. Majority of population were women (>
70%) so not particularly generalisable.
Study attrition Unclear No evaluation of people excluded vs included. No comparison of missing val-
ues against anticholinergic burden score.
Prognostic factor mea-
surement
Unclear Repeated measurements conducted (at each follow-up assessment). Medica-
tion assessed using only 1 method (self-report). No measurement of dosage
and frequency of use.
Outcome measurement Unclear Anticholinergic burden likely measured after cognitive assessment complete
(medications recorded before each evaluation but was part of religious order
study so anticholinergic burden not primary focus during assessments).
Study confounding Unclear Only controls for age, sex, and education in primary analysis. Did not control
for any comorbidities, despite measuring these.
In secondary analysis it then controls for covariates but is restricted to inci-
dent anticholinergic drug users only.
Reverse causation No No restrictions placed on time frame of anticholinergic drug use before cogni-
tive assessment.
Shah 2013  (Continued)
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Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: Taiwan
Duration of follow-up: 4 years
Covariates controlled for: age, sex, duration of Parkinson's disease before index date, conditions (hy-
pertension, stroke, hypercholesterolaemia, diabetes mellitus, depression, anxiety, psychotic-related
disorder, alcohol-related disorder, sleep disorder, and head injury), and medications (antihyperten-
sives, antidiabetics, anticoagulants, antihyperlipidaemics, antidepressants, benzodiazepines, and an-
tipsychotics)
Participants Participants numbers: 1232
Population type: people with Parkinson's disease
Sex: 44% women (542)
Age (mean): not stated
Prognostic factors Anticholinergic burden measurement method: ACB scale
Outcomes Outcomes assessed: dementia
Outcome ascertainment dementia: clinical codes recorded in medical records
Diagnostic criteria dementia: ICD-9-CM codes 290.0–290.4, 294.1, 331.0–331.2
Source of funding Ministry of Science and Technology
Notes  
 
Item Authors' judgement Support for judgement
Study participation No Parkinson's disease population.
Study attrition Unclear No mention of attrition.
Prognostic factor mea-
surement
Unclear Relied on prescription records. Measured cumulative dose over 3-year expo-
sure period.
Outcome measurement Unclear Relied on database diagnoses.
Study confounding Yes All relevant covariates controlled for.
Reverse causation Unclear Excluded participants taking anticholinergic drugs 1 year before diagnosis.
Sheu 2019 
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Statistical analysis and re-
porting





Methods Design: retrospective cohort
Setting: community
Country: UK
Duration of follow-up: 6.25 years
Covariates controlled for: age and childhood IQ for linear regression; age, sex, family history of demen-
tia, education, heart history, blood pressure history, ApoE e4 for logistic regression
Participants Participants numbers: 281
Population type: older adults
Sex: 42% women (119)
Age (mean): 77 years
Prognostic factors Anticholinergic burden measurement method: literature review of drugs' mean anticholinergic activity
Outcomes Outcomes assessed: dementia; cognitive decline
Outcome ascertainment dementia: consensus diagnosis based on multidisciplinary evaluation
Outcome ascertainment cognitive decline: MMSE and cognitive test battery of 5 cognitive tests
Diagnostic criteria dementia: ICD-10 criteria
Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding Wellcome Trust
Notes  
 
Item Authors' judgement Support for judgement
Study participation Unclear Adequate reporting of age, sex, and comorbidities. However, limited age range
included (77–82 years).
Study attrition No 281/324 participated. Only 136/281 (48%) participants had complete cognitive
data sets available after follow-up.
Prognostic factor mea-
surement
Unclear Relied on patient self-report.
Outcome measurement Unclear No blinding but anticholinergic burden score likely applied in retrospect.
Study confounding Unclear No control for depression.
Whalley 2012 
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Reverse causation Unclear Excluded people with lower MMSE at baseline from analysis. Follow-up 15
months minimum after baseline anticholinergic measurement taken.
Statistical analysis and re-
porting
No Model was underpowered to assess dementia association (only 45 cases of de-





Methods Design: retrospective case-control
Setting: community and outpatient
Country: UK
Duration of follow-up: 1.5 years
Covariates controlled for: age, gender, years of education, disease duration, MDS-UPDRS III, levodopa
equivalent daily dose and GDS-15 (note: unclear what was controlled for in final model)
Participants Participants numbers: 219
Population type: people with Parkinson's disease
Sex: 40% women (88)
Age (mean): 69 years
Prognostic factors Anticholinergic burden measurement method: ADS scale
Outcomes Outcomes assessed: MCI; cognitive decline
Outcome ascertainment MCI: not clear
Outcome ascertainment cognitive decline: MMSE, MoCA, in addition to tests of attention, visual memo-
ry, executive, language and visuospatial function
Diagnostic criteria MCI: PD-MCI was determined using the MDS criteria
Diagnostic criteria cognitive decline: scores on cognitive testing
Source of funding Parkinson's UK grant
Notes  
 
Item Authors' judgement Support for judgement
Study participation No Parkinson's disease population.
Study attrition Unclear No comparison of completers vs non-completers.
Prognostic factor mea-
surement
Unclear Not particularly clear how prognostic factor was measured but seems to be
self-report. Repeated measurements taken at baseline and 18 months.
Outcome measurement Unclear No blinding but ADS ratings likely assigned in retrospect.
Yarnall 2015 
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Study confounding Yes Appropriate variables controlled for.
Reverse causation No ADS at baseline and at 18 months pooled so no restriction on ADS use before
cog assessment at 18 months.
Statistical analysis and re-
porting
No Uses backward stepwise regression to determine model covariates for use in
exploring ADS association with various measures of cognition. Not stated what
variables were controlled for in the final model.
Yarnall 2015  (Continued)
ACB: Anticholinergic Cognitive Burden; ACT: Adult Changes in Thought; ADS: Anticholinergic Drug Scale; AGECAT: Automated Geriatric
Examination for Computer Assisted Taxonomy; ANDI: Alzheimer's Disease Neuroimaging Initiative; ApoE: apolipoprotein E; ARS:
Anticholinergic Risk Scale; BMI: body mass index; CAD: coronary artery disease; CES-D: Center for Epidemiologic Studies Depression
Scale; CHF: congestive heart failure; COPD: chronic obstructive pulmonary disease; CNAM-TS: Caisse Nationale d'Assurance Maladie des
Travailleurs Salariés; CRF: cardiovascular risk factor; DBI-ach: anticholinergic component of the Drug Burden Index; DSM-III: Diagnostic and
Statistical Manual of Mental Disorders Third Edition; DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders Third Edition Revised;
DMS-IV: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition; DSM-5: Diagnostic and Statistical Manual of Mental Disorders
FiKh Edition; ED: emergency department; GDS: Geriatric Depression Screen; GP: general practitioner; HVRT: Hopkins Verbal Recall Test;
IADL: instrumental activity of daily living; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10:
International Classification of Diseases, Tenth Revision; MCI: mild cognitive impairment; MDS-UPDRS III: Motor Rating Scale – Unified
Parkinson's Disease Rating Scale III; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; NIH: National Institutes
of Health; NINCDS-ADRDA: Association Internationale pour la Recherche et l'Enseignement en Neurosciences; PD-MCI: Parkinson's disease
mild cognitive impairment; VA: Veteran's AFairs.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aalto 2018 Wrong study design.
Andrade 2019 Wrong study design.
Andre 2019 Wrong patient population.
Ang 2015 Abstract only.
Ang 2017 Wrong patient population.
Aparasu 2014 Wrong patient population.
Asano 2019 Abstract only.
Ben Omar 2013 Abstract only.
Bostock 2013 Wrong study design.
Bottiggi 2006 Dichotomises anticholinergics.
Bouchard 2017 Grey literature (dissertation).
Broder 2020 Abstract only.
Cai 2013 Repeat data set of already included study.
Campbell 2010 Repeat data set of already included study.
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Study Reason for exclusion
Campbell 2018 Repeat data set of already included study.
Cancelli 2008 Wrong study design.
Cao 2008 Wrong study design.
Cardwell 2020 Wrong prognostic factor (DBI-ach not reported separately).
Carriere 2009 Dichotomised anticholinergic burden.
Cherniaeva 2019 Abstract only.
Cooley 2020 Duplicate.
Cooley 2021 Wrong population.
Dmochowski 2021 Wrong study design (systematic review).
Drag 2012 Abstract only.
Ehrt 2010 Wrong patient population (baseline dementia = 20% for community dwelling population).
Fox 2011b Wrong patient population.
Gnjidic 2012 Wrong prognostic factor (DBI-ach not reported separately).
Hanlon 2020 Wrong population (middle aged).
Hong 2019 Dichotomised anticholinergic burden.
Huang 2012 Non-English language.
Jakeman 2020 Conference abstract.
Kada 2019 Non-English language.
Kamkwalala 2020 Abstract only.
Kar 2004 Wrong study design (review).
Kashyap 2013 Abstract only.
Khan 2021 Wrong study design.
Lampela 2013 Wrong study design.
Lattanzio 2018 Wrong outcome.
Lavrador 2020 Duplicate.
Lavrador 2021 Wrong study design (duration of follow-up too short).
Lawson 2015 Abstract only.
Lechevallier-Michel 2005 Wrong study design.
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Study Reason for exclusion
Liu 2020 Repeat data set of already included study.
Lucas 2016 Abstract only.
Naharci 2017 Wrong patient population.
Neelamegam 2020 Repeat data set of already included study.
Nishtala Prasad 2020 Wrong patient population.
Park 2017 Repeat data set of already included study.
Pasina 2013 Wrong study design (follow-up only for Barthel index; none for cognition).
Pasina 2020 Wrong study design.
Perez 2019 Abstract only.
Pfistermeister 2017 Wrong study design.
Richardson 2018b Abstract only.
Rudolph 2008 Wrong outcome.
Salyer 2019 Wrong study design.
Shetty 2020 Abstract only.
Shiota 2020 Wrong study design.
Suh 2020 Repeat data set of already included study.
Tanaka 2019 Non-English language.
Tristancho-Perez 2019 Abstract only.
Tsoutsoulas 2017 Wrong study design.
Verdoux 2020 Wrong population.
Wang 2019 Repeat data set of already included study.
Weigand 2020 Repeat data set of already included study.
Welk 2020 Dichotomises anticholinergic use.
Wouters 2017 Wrong prognostic factor (DBI-ach not reported separately).
Wouters 2020 Wrong prognostic factor (DBI scale; anticholinergic not reported separately).
Ziad 2021 Wrong patient population (middle-aged adults).
DBI: Drug Burden Index; DBI-ach: anticholinergic component of the Drug Burden Index.
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A D D I T I O N A L   T A B L E S
 
Population Older adults (mean age ≥ 50 years) free of cognitive impairment at baseline
Interventions Anticholinergic burden as measured by any validated ordinal anticholinergic burden scale
Comparators (covariates of in-
terest)
Age, sex, and comorbidity
Outcomes Incident dementia or cognitive function (multidomain)
Type of study Longitudinal, observational cohort/case-control
Timing and setting Recruitment from primary, secondary, or community settings
Minimum of 1-year follow-up




(circle 1 for each
criterion)
Footnotes
(explain reasons for upgrading or downgrading)
Quality of the evi-
dence
(circle 1 per out-
come)
Prognostic factor: anticholinergic burden (defined by ACB scale) and risk of future cognitive impairment/dementia in cogni-
tively healthy older adults
Phase of investiga-
tion
No issues Most studies were phase 3 confirmatory investigations.
Study limitations Serious (–1) 2 studies were at high risk of bias, with issues around reverse
causation. The remaining 2 studies were at unclear risk of bias,
1 of which had uncertain risk of bias due to reverse causation.
Imprecision Serious (–1) Relatively wide confidence intervals.
Inconsistency No issues Included studies were predominantly assessed using similar
prognostic outcome measures, definitions, in similar settings
with similar follow-up durations. Direction of effect was also
consistent.
Indirectness No issues Included studies represented the review question adequately.
Publication bias Serious (–1) Publication bias was assumed.
Effect size No Moderate effect size in primary analysis but lower bound confi-
dence intervals suggested a low effect size.
Dose-response
gradient
Yes (+1) Clear relationship between severity of ACB scale score and risk





Table 2.   GRADE 
ACB: Anticholinergic Cognitive Burden.
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A P P E N D I C E S
Appendix 1. Anticholinergic burden scales
AAS: Anticholinergic Activity Scale
AAS-r: Revised Anticholinergic Activity Scale
ABC: Anticholinergic Burden Classification
ABS: Anticholinergic Burden Scale
ACB: Anticholinergic Cognitive Burden
ADS: Anticholinergic Drug Scale
AEC: Anticholinergic EFect on Cognition
AIS: Anticholinergic Impregnation Scale
ALS: Anticholinergic Loading Scale
ARS: Anticholinergic Risk Scale
BAAS: Brazilian Anticholinergic Activity Scale
Chew's list
CrAS: Clinician-rated Anticholinergic Scale
Ellett's list
KABS: Korean Anticholinergic Burden Scale
MARANTE: Muscarinic Acetylcholinergic Receptor Antagonist Exposure Scale
mARS: Modified Anticholinergic Risk Scale
Appendix 2. Contributions to Delphi
Contributors to Delphi for selection of adjustment variables were researchers and clinicians from a range of specialities (medicine and
psychology). Specific contributors were Dr Carrie Stewart, Dr Roy Soiza, Professor Phyo Myint, Dr Terry Quinn, and Dr Yoon Loke.
Appendix 3. Sources searched and search strategies
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13. ("chew* score" or "chew* list").ti,ab.



















33. Mild Cognitive Impairment/







41. major neurocognitive disorder*.ti,ab.
42. minor neurocognitive disorder*.ti,ab.
43. neurocognitive dysfunction.ti,ab.
  (Continued)
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44. Neurocognitive Disorders/
45. or/16-44
46. 15 and 45
EMBASE (OvidSP) from
1974













12. ("chew* score" or "chew* list").ti,ab.
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32. Mild Cognitive Impairment/







40. major neurocognitive disorder*.ti,ab.




45. 14 and 44
PsycINFO (OvidSP) from
1806













12. ("chew* score" or "chew* list").ti,ab.
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25. (speed adj2 processing).ti,ab.
26. memory.ti,ab.
27. exp Memory Disorders/
28. "episodic memory".ti,ab.
29. exp Episodic Memory/
30. exp Cognitive Impairment/
31. MCI.ti,ab.
32. exp Cognitive Assessment/







40. major neurocognitive disorder*.ti,ab.
41. minor neurocognitive disorder*.ti,ab.
42. neurocognitive dysfunction.ti,ab.
43. exp Neurocognitive Disorders/
44. or/15-43
45. 14 and 44
CINAHL (EBSCOhost)
Date of search: 24
March 2021
S1 TX cholinergic antag*
S2 TX anticholinergic*
S3 TX anti-cholinergic*








S12 TX "chew* score" or "chew* list"
S13 TX "han's score" or "han score"
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S21 TX "lewy bod*"
S22 TX FTLD
S23 TX PDD
S24 TX "executive function*"
S25 (MH "Attention")
S26 TX speed AND processing
S27 TX memory
S28 (MH "Memory Disorders")
S29 TX "episodic memory"
S30 (MH "Memory Disorders") OR (MH "Memory")
S31 TX MCI
S32 "Mild Cognitive Impairment"







S40 TX major neurocognitive disorder*
S41 TX minor neurocognitive disorder*
S42 TX neurocognitive dysfunction
S43 "Neurocognitive Disorders"
S44 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24
OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34
OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43
S45
S14 AND S44
Web of Science core col-
lection
(ISI Web of Science)
Date of search: 24
March 2021
TOPIC: ("cholinergic antag*" OR anticholinergic* OR "anti-cholinergic*" OR
AAS OR ACB OR ADS OR DAPs OR ARS OR "DBI-ACh" OR SAMS OR "chew* score"
OR "chew* list" OR "hands score" OR "hans score" OR "han score") AND TOPIC:
(cognit* OR dement* OR alzheimer* OR "lewy bod*" OR FTLD OR PDD OR "ex-
ecutive function*" OR attention OR memory OR MCI OR "major neurocognitive
disorder*" OR "minor neurocognitive disorder*")
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH,
BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC.
Mar 2020: 1348
Mar 2021: 646
TOTAL before deduplication Mar 2020: 14,517
Mar 2021: 1874
TOTAL after deduplication Mar 2020: 9767
Mar 2021: 1493




Appendix 4. Contents of proforma
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Extracted information Included details
General information Author, title, source, publication date, language, related or duplicate publications.
Source of data Cohort (retrospective or prospective data collection), case-control, randomised trial, or secondary
analysis of registry data.
Participant information Participant eligibility and recruitment method (e.g. consecutive or other recruitment, number of
centres, inclusion and exclusion criteria); participant demographics (e.g. age, sex); details of ongo-
ing treatments/medications; study dates; country of recruitment; setting (using our definitions of
primary, secondary, and community settings).
Prognostic factor Definition and method of measurement of prognostic factor. Duration of exposure (pre- or post-
study commencement) was not regularly recorded; however, where possible, we recorded timing
of prognostic factor measurement (number of weeks participants had been on the anticholinergic
drugs prior to baseline assessment); where data were available, we also collected duration of expo-
sure during the study.
Outcomes to be predicted Definition and method of measurement of outcome; time of outcome ascertainment, or summary
of duration of follow-up.
Adjustment for other prognos-
tic factors (covariates)
List of all the covariates that were adjusted for in any regression model.
Sample size Number of participants and number of outcomes/events; how missing data were handled (e.g.
complete-case analysis, imputation, or other methods).
Reported results We recorded incidence of dementia and cognitive decline. Where possible, we extracted estimates
and corresponding confidence intervals from each included paper. We also recorded overall sur-
vival (including duration of follow-up) and dementia-free survival (including duration of follow-up).
 
 
Appendix 5. QUIPS (Quality in Prognosis Studies) anchoring statements
Specific considerations
• Study participation: we considered whether the method of recruitment was at risk of selection bias (e.g. consecutive recruitment versus
convenience sample) and if there was adequate reporting of comorbidities and demographics (age and sex). If either a convenience
sample was used or there was inadequate reporting of comorbidities/demographics, we assigned a moderate risk of bias.
• Attrition: we anticipated that most studies would utilise databases, hence attrition was less of an issue. Therefore, we focused on
reporting of, and methods for dealing with, missing data. We assigned a moderate risk of bias if no analysis was carried out to evaluate
if participants with missing data diFered in baseline anticholinergic burden score compared to those with full data.
• Prognostic factor measurement: we considered how medication data were obtained. If medication was not established via at least two
methods and capable of establishing non-prescription medications taken, along with duration of exposure and adherence, we assigned
a moderate risk of bias. If repeated anticholinergic burden measurements were not made over time for studies with a follow-up duration
of more than one year, we assigned a high risk of bias. We anticipated that some studies would utilise validated anticholinergic burden
scales but adjust these scales, for instance to incorporate dosage into the anticholinergic calculation. We did not consider utilisation of
anticholinergic burden scales as part of the 'Risk of Bias' assessment, as it is the purpose of the review to establish which anticholinergic
burden scales have the greatest prognostic accuracy.
• Outcome measurement: we considered the method utilised for dealing with missing data in relation to the outcome. If 'last diagnosis
carried forward' was used when final outcome data were not available, we assigned a high risk of bias. We assessed whether the outcome
was established via a clinical follow-up or was reliant upon database diagnoses. If outcome was reliant upon database diagnoses alone,
we assigned a moderate risk of bias. We also assessed if the outcome was determined without knowledge of the prognostic factor. If
there was no blinding to outcome and the cognitive diagnosis was conducted aKer the anticholinergic burden measurement was taken,
we assigned a high risk of bias; if the cognitive diagnosis preceded the anticholinergic burden measurement, we assigned a moderate
risk of bias.
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• Covariates: we assessed whether studies adjusted for age, sex, and comorbidities as a minimum. If these covariates were not adjusted
for, we assigned a high risk of bias. Assessment for comorbidities required control for at least three comorbidities that covered both
physical and psychiatric domains; failure to do so resulted in a rating of moderate risk of bias.
• Reverse causation: we evaluated studies regarding perceived risk that anticholinergic drug use was prescribed for treatment of early
signs of dementia. If studies did not explicitly report restricting anticholinergic burden measurement to at least 12 months before
dementia onset, a rating of high risk of bias was applied. If studies imposed restrictions of anticholinergic burden measurement for one
to two years before the dementia index date, a moderate risk of bias rating was applied.
• Statistical analysis: we evaluated how the analysis was conducted. Specific issues of consideration in each area were decided upon via
discussion among the review authors. We assigned a high risk of bias if: a multivariate analysis was not conducted; if the analysis was not
appropriately powered based on the '10 events per covariate' rule; if the method for selecting covariates for inclusion in a multivariate
model was based on P values in a univariate analysis without incorporation of prior knowledge of relevant associations into selection;
if the method of analysis was inconsistent with the stated protocol; and if the reported results were inconsistent with the stated method
of analysis. We assigned a moderate risk of bias if relevant assumptions were not checked.
H I S T O R Y
Protocol first published: Issue 2, 2020
Review first published: Issue 4, 2021
C O N T R I B U T I O N S   O F   A U T H O R S
TQ conceived the idea.
ANS conducted the search.
MT and SE screened the search results, selected studies for inclusion and exclusion, and performed data extraction and 'Risk of bias'
assessment for each study.
MT conducted the analysis and wrote the manuscript.
PM, TQ, JM, RS, CS, and YL contributed to data interpretation and the writing of the manuscript.










S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NIHR, UK
This protocol was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane
Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not necessarily
reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health
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• The Dunhill Medical Trust, UK
This work was supported by a Dunhill Medical Project Grant (RPGF1806/66)
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We made some minor changes to our review process to those specified in the protocol (Quinn 2020).
• Four review authors joined the review team (SE, ANS, RS, and YL).
• We did not employ the I2 statistic to evaluate heterogeneity in included studies, choosing instead to evaluate heterogeneity narratively.
This was due to evidence that the I2 statistic can exaggerate levels of heterogeneity in prognostic research.
• We decided not to report mortality, overall survival or dementia-free survival as secondary outcomes on the basis that we found very
few data on this in included reviews and since mortality has already been the focus of other recently published systematic reviews.
• We conducted a sensitivity analysis restricted to studies with no 'high risk of bias' categories, rather than restricted to studies at 'low
risk of bias' overall, due to the lack of studies judged at low risk of bias.
• We added additional criteria to our outcome risk of bias and reverse causation evaluation. Specifically, if the cognitive diagnosis
preceded the anticholinergic burden measurement, we assigned a moderate risk of bias to the outcome. If studies imposed a restriction
on anticholinergic drug use to one to two years before the dementia index date, we applied a moderate risk of bias rating.
• We were unable to perform our planned meta-regressions due to lack of study numbers. Similarly, we could not pool linear or hazard
ratio outcome data, investigate the association between anticholinergic burden, and duration of exposure due to insuFicient data.
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